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Insomnia is a debilitating condition that can cause severe psychological distress and is 
frequently comorbid with other mental health conditions. Although psychological 
treatment is effective, it is hindered by cost and availability, while hypnotic sleep 
medications are recommended for time-limited use and can impair day-time 
functioning. For these reasons, investigation into alternative treatment options for 
sleep difficulties is necessary. The present study examined the effect of a multi-
ingredient micronutrient formula called Daily Self Defense (revised formula of 
EMPowerplus) on adults suffering from insomnia; following a multiple baseline 
design. The final sample comprised 14 participants, aged 18 years or older, who were 
randomised into one of three baseline groups; ranging from one to three weeks in 
length. Following the baseline phase, participants took part in an open-label trial of 
Daily Self Defense for eight weeks; after which a three month follow-up was 
conducted. Although there was a trend towards a small improvement during baseline 
phase for some measures, there was much greater improvement during the 
intervention phase. Time series graphs and Modified Brinley plots revealed decreases 
in insomnia severity, depression, stress and anxiety for 10 out of 12 participants who 
completed the intervention phase. Cohen’s d, and the percentage of participants 
showing reliable positive change, confirmed moderate or large effect sizes for all 
outcome variables. Furthermore, of 12 participants who completed the intervention 
phase, all were compliant with taking the capsules, and any side effects experienced 
were mild and transitory. This study provides evidence for the potential of 
micronutrient interventions in effectively treating insomnia in adults. It also indicates 
the need for future research utilising placebo-controlled designs as well as 





1.1 Background to Insomnia  
Chronic insomnia is a condition estimated to affect between 12 to 15% of the adult 
population, and as many as 50% of those in primary health care settings (Blampied & 
Bootzin, 2013). A national survey found that 13% of New Zealanders aged 20-59 years are 
affected by insomnia (O’Keeffe, Gander, Scott, & Scott, 2012), and that Maori are affected 
disproportionately with a prevalence of 19.1% compared with 8.9% for non-Maori. Insomnia 
is a debilitating condition that causes severe psychological distress, depression, physical and 
mental illness, impaired functioning and loss of focus and productivity (Bootzin & Epstein, 
2011). As humans, sleep is vital to our functioning and well-being. The cognitive processes 
and neural activity that occur during sleep are necessary for appropriate brain growth and 
function, and a lack of quality sleep can play havoc with an individual's health, mood, 
emotions and energy. Good quality sleep, of an adequate length, is vital for the functioning 
and well-being of the human brain. Unfortunately, insomnia, or the inability to regularly 
obtain sleep of sufficient frequency, length and quality, is the most common sleep problem 
among adults and one of the most prevalent health problems faced in the 21st century 
(Ancoli-Israel & Roth, 1999). Its prevalence increases with age, and women are more likely 
to be affected than men , at a rate of 24% vs. 14% (Touitou, 2007). 
  The core complaints of individuals with insomnia are that they have difficulty 
initiating sleep, they wake often during the night, or they have poor sleep quality that is 
unrefreshing. Insomnia can last for episodes of several days, several weeks, or chronic 
episodes of months and years (Rothenberg, 1997). The Diagnostic Statistical Manual of 
Mental Disorders – Fifth Edition (APA, 2013) requires that insomnia is characterised by 
difficulty initiating or maintaining sleep, or early morning waking with the inability to return 
to sleep, that occurs at least three nights per weeks and has been present for at least three 
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months. This sleep disturbance (or associated daytime fatigue) causes clinically significant 
distress or impairment in social, occupational, or other important areas of functioning. 
 
1.1.1 Aetiology of Insomnia. While the exact causes of an individual's insomnia 
may vary, the majority of research identifies heightened arousal, anxiety, worry and 
rumination, as being leading factors in the cause and maintenance of sleep disruption 
(Bootzin & Epstein, 2011). Daytime events, especially those that are emotionally stressful 
have been found to impact sleep quality and wellbeing. These are thought to do so through 
triggering cortical and emotional arousal which in turn disrupts sleep pattern, also shortening 
the amount of REM sleep, which is thought to play a role in regulating emotion (Wuyts et al., 
2012). Several psychological and physiological aspects are thought to contribute to the onset 
and maintenance of insomnia; anxious-ruminative traits, life stressors, homeostasis 
weakening mechanisms, menopause, and biologic or genetic central nervous system hyper-
arousal have all been identified as factors that can be involved (Basta, 2007). 
The most widely accepted model for the development and maintenance of insomnia 
comes from the 3-P’s model proposed by Spielman (1991), suggesting that three distinct 
elements contribute to the onset and course of insomnia. The model indicates that 
predisposing factors such as acquired or inherited characteristics can make an individual 
more susceptible to develop a sleeping disorder. It suggests that precipitating events or life 
stressors such as health problems, family or marital conflict, and work or school stress can 
trigger the onset of insomnia, and that dysfunctional attitudes and behaviours around sleep 
can perpetuate and maintain these sleep difficulties. According to this model, insomnia may 
become  independent of its initial cause over time (Basta, 2007). 
Traits such as hyper- arousal, or hereditary genetics can influence an individual’s 
vulnerability for developing insomnia (Bootzin & Epstein, 2011). Genetic studies have 
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identified genes that are likely to be important in the regulation of circadian rhythms and 
henceforth influence the time of sleep onset and waking (Taheri & Mignot, 2002). Hyper- 
arousal, particularly cognitive hyper-arousal, has been identified as a particularly significant 
vulnerability factor, and those with insomnia have been found to have higher levels of 
cognitive arousal and feel less sleepy in the bedroom than those who report normal sleep 
(Robertson, Broomfield, & Espie, 2007).  
Neuroimaging studies have found that individuals with insomnia show a pattern of 
increased subcortical brain activation during sleep, and decreased prefrontal cortical 
activation when awake (Nofzinger et al., 2004). In a study comparing individuals with 
insomnia to healthy participants, those with insomnia showed a greater global cerebral 
glucose metabolism during sleep and while awake. They also showed a smaller decrease in 
relative metabolism between waking to sleep states, and reduced relative metabolism in the 
prefrontal cortex when awake (Nofzinger et al., 2004). These differences may be due to a 
failure of arousal mechanisms in insomniacs which are responsible for the reduction in 
activity from waking to sleep states. 
Changes to circadian rhythm and homeostatic processes have also been identified as 
potential causal mechanisms for sleep difficulties. These processes regulate sleep and wake 
cycles and a dysregulation to them may cause an imbalance in time spent awake and asleep. 
The circadian clock, which is located in the nucleus of the hypothalamus, uses environmental 
cues such as light, routine, food consumption and social interaction to regulate circadian 
rhythms. Sleep behaviours that are developed in response to insomnia, for example 
stimulating night time activities or food consumption, may interrupt the environmental cues 




Precipitating factors including family, work, school and ill health are all stressors that 
may affect an individual’s sleep (Bootzin & Epstein, 2011). Highly stressful life events have 
been found to be closely associated with the onset of insomnia. The impact of these stressors 
is mediated by certain predisposing personality traits, individuals with insomnia (compared to 
controls) have been found to overall be more discontent (both as children and adults), rate 
their interpersonal relationships as less satisfying, have poorer self-concept, and have 
maladaptive coping skills for dealing with stress (Basta, 2007). 
The way in which an individual responds to these stressors and to sleep difficulties 
themselves, in the form of rumination and worry, can cause an acute sleep problem to 
become a chronic condition.  Dysfunctional or maladaptive cognitive processes, including 
negative cognitions around sleep, can both exacerbate and perpetuate insomnia symptoms 
(Belanger, Savard, & Morin, 2006). A significant feature of those who suffer from chronic 
insomnia is the frequent presence of intrusive and worrisome thinking, which is thought to 
both cause and maintain insomnia symptoms (Morin, Stone, Trinkle, Mercer, & Remsberg, 
1993). A study examining the role of beliefs and attitudes about sleeping in 145 adults, found 
that those who suffered from insomnia endorsed stronger beliefs about the negative 
consequences of poor sleep, expressed more hopelessness in regards to fear of losing control 
over their sleep, and expressed more helplessness about its unpredictability. The findings 
suggest that some beliefs and attitudes towards sleep may be playing a role in the 
perpetuation of insomnia symptoms (Morin et al., 1993). 
Behaviours around sleeping have also been found to play a role in the maintenance of 
sleep difficulties. Extended time in bed, irregular sleep-wake schedules, daytime napping, 
and non-sleep behaviours in the bedroom environment (using technology, working) have all 




1.1.2 Adverse effects on health. While there is still much to be understood about the 
nature of sleep processes, it is evident that the cognitive processes, neural activity and 
metabolism that occur during this state are vital to the healthy growth, nurture and 
maintenance of the brain (Hobson, 2005). Disturbed sleep, whether due to quality, timing or 
duration, can cause many adverse health concerns. The most obvious are fatigue and 
impaired cognitive function, but mood is also greatly affected (APA, 2013). Short sleep 
duration has is also a risk factor for increased body mass, metabolic dysfunction, type 2 
diabetes and hypertension (O’Keeffe et al., 2012). 
An individual not obtaining enough quality sleep suffers severe negative 
consequences in mood, cognitive function, memory, emotion regulation, attention, energy, 
productivity and physical health. When co-morbid with other psychological conditions 
(which it often is), insomnia has a strong impact on an individual's quality of life and on their 
health. Individuals with insomnia are likely to take more medications, need more healthcare 
resources, be absent from work due to illness more often, and have more work-related and 
motor vehicle accidents (Ancoli-Israel & Roth, 1999; O’Keeffe et al., 2012). In New Zealand, 
the estimated annual savings associated with effectively treating all people with insomnia 
between ages 20-59, is $21.8 million (O’Keeffe et al., 2012). 
The processes of sleep and circadian rhythms determine daily physiological patterns 
and have an important impact on metabolic health (Depner, Stothard, & Wright, 2014). 
Insufficient sleep associated with insomnia can contribute to the dysregulation of the 
metabolic system and can contribute to weight gain, obesity and type 2 diabetes through 
altering the timing and quantity of food intake. Sleep deficiency associated with  metabolic 
dysregulation can also lead to the disruption of energy balance, increase inflammation, 
impaired glucose tolerance and insulin sensitivity (Depner et al., 2014) 
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Sleep disturbance is so interrelated with a person's overall functioning that it is 
considered 'trans-diagnostic' in that it significantly increases the risk for co-morbid disorders, 
including anxiety and depression (Harvey, Eidelman, & Talbot, 2008; Sarsour et al., 2010). 
Insomnia is repeatedly found to occur with a range of psychological disorders, and those with 
insomnia report more day time symptoms of depression and anxiety than good sleep control 
subjects (Morin et al., 2006) . 
Depression is over-represented among populations with sleep disorders (O’Keeffe et 
al., 2012). Even though sleep difficulties are a symptom of depression, insomnia or sleep 
problems sometimes appear prior to an episode of depression. There are bi-directional 
associations between insomnia and depression that can make it hard to differentiate cause and 
effect interactions between the two disorders (Franzen & Buysse, 2008). Studies using 
longitudinal data have shown that insomnia is a risk factor for developing depression and that 
the combination of insomnia and depression increases episode severity and duration of 
depression(Franzen & Buysse, 2008).  
The impact of sleep disruption on mood has been found across many studies. In an 
epidemiological study conducted in Switzerland, subjects were interviewed six times over the 
course of 20 years, and it was found that those who had experienced insomnia for two weeks 
or longer had a higher risk for later developing depression  (Franzen & Buysse, 2008). 
 In a pilot study examining the relationships between sleep deprivation on sleepiness, 
affect and psychomotor vigilance, sleep deprivation had a significant impact on all three 
domains (Franzen, Siegle, & Buysse, 2008).  
Sarsour and colleagues (2010) conducted a study investigating the associations 
between insomnia severity and depression. Five hundred and forty one participants suffering 
non-restorative sleep were compared with 717 subjects who had never experienced sleep 
difficulties, and non-restorative sleep was found to significantly impact emotional function.  
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In a study investigating the impact of sleep deprivation on aspects of affective 
functioning in healthy adolescent and adults, it was found that lack of sleep resulted in less 
positive affect compared to rested controls, on nine out of twelve positive affect items. 
Participants who were deprived of sleep also reported a greater increase in anxiety during a 
catastrophizing task and rated the likelihood of potential catastrophes as more likely when 
sleep deprived compared to the rested condition (Talbot, McGlinchey, Kaplan, Dahl, & 
Harvey, 2010).  
There is a close relationship between emotional and mental disorders, daily stress, and 
sleep disorders, which must be recognised to increase the effectiveness of interventions 
(Rothenberg, 1997). The frequency of sleep complaints in the general population, the variety 
of causes, and the significant overlap between the complaints of patients with sleep disorders 
and the complaints of patients with mental disorders, makes it an extremely important area of 
continuing research in the mental health field (Rothenberg, 1997). 
 
1.2 Current Treatments 
 
 
1.2.1 Behavioural and Psychological Interventions. Behavioural treatments for 
insomnia target appropriate sleep education, hygiene, and cognitive process that inhibit sleep. 
It is thought that sleep difficulties may arise because appropriate sleep hygiene behaviour or 
stimulus control have not been established (Blampied & Bootzin, 2013). Stimulis control 
therapy (SCT) is often used as a treatment for insomnia and involves ensuring that stimuli in 
the bedroom encourage sleep, rather than disrupt it; for example limiting use of internet, 
televisions or computers in the bedroom (Haynes & Bootzin, 2010).  
  Patients can benefit from many behavioural treatments including 
restructuring their bedtime habits and sleep-wake schedules, restricting time in bed, and 
relaxation training. A vast majority of insomnias can be reduced to some extent by adhering 
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to sleep hygiene rules such as keeping regular sleep hours, going to bed only when sleepy, 
exercising regularly later in the day, avoiding stimulants near bedtime, and minimising light, 
noise, and extremes in temperature in the bedroom (Rothenberg, 1997). In several sleep clinic 
settings, time and cost constraints ensue that clinicians are required to provide treatment 
suggestions for patients that they will see only for a few sessions, thus, many of their 
recommendations focus on sleep hygiene (Bootzin & Rider, 1997). Although sleep hygiene is 
an important factor in treatment and must not be over looked, there are limitations to what it 
can achieve. A meta-analysis of 59 treatment outcome studies, evaluating non-
pharmacological treatments for insomnia, found that sleep hygiene as a single intervention 
was not effective, and that stimulus control and sleep restriction were the most effective 
behavioural treatments (Morin, Culbert, & Schwartz, 1994). 
Sleep hygiene, education and stimulus control are regarded as necessary but not 
sufficient, in the effective treatment of sleep disorders. Other treatment techniques focus on 
reducing the individual's levels of stress and arousal, through relaxation, meditation and 
progressive muscle relaxation. Cognitive behaviour therapy (CBT) is used to target the 
maladaptive beliefs, mind-racing, and ruminative worry, thought to contribute to sleep 
difficulties (Haynes & Bootzin, 2010; Morin et al., 2006). 
The role of emotional, behavioural and cognitive factors in insomnia is receiving 
increasing recognition and resulting in the increased use of CBT for the management of 
insomnia (Belanger et al., 2006). CBT for insomnia focuses on reducing sleep-incompatible 
behaviours, managing arousal, and restructuring sleep-related dysfunctional cognitions. CBT 
has been studied in extensive controlled evaluations and has become the treatment of choice 
among psychological treatments for insomnia (Morin et al., 2006). Controlled clinical trials 
show that 70-80% of patients with primary insomnia benefit from CBT intervention and that 
these improvements are sustained over time (Belanger et al., 2006; Morin, Colecchi, Stone, 
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Sood, & Brink, 1999; Morin et al., 1994; Morin, Hauri, et al., 1999; Murtagh & Greenwood, 
1995). 
Although cognitive behavioural interventions can produce effective and sustained 
results, they are largely self-directed treatment approaches and rely heavily on the individual 
to maintain practice of techniques and behaviours in their own home. Cognitive and 
behavioural therapies also rely on the individual’s access to a clinical therapist which can be 
both costly and timely and, given the lack of publically funded therapy, it is not always 
available to all members of the population.  
 
1.2.2 Pharmacological Interventions.While behavioural and cognitive approaches, 
when used together, can effectively treat insomnia, pharmacological treatment is still the 
most widely available form of treatment. A wide range of medications and non-prescription 
treatments are available that exhibit their effect through the action of sedation. The most 
commonly prescribed are those that affect the GABA neurotransmitter such as 
benzodiazepines which are anxiolytic, and newer “z” hypnotics such as zolpidem, zaleplon 
and zopiclone. These medications selectively affect the GABA neurotransmitter and have a 
hypnotic or sedating effect, or both (Bootzin & Epstein, 2011).  
There are several limitations to the pharmacological treatment options available; 
hypnotics often cause daytime impairment and sedation due to their half-life, which interferes 
with a person's daily functioning, energy and mental clarity (Sateia & Nowell, 2004). 
Furthermore, benzodiazepines and hypnotics are only safe and effective for short term use, as 
after this a tolerance develops and the therapeutic effect of the drug wears off, 
benzodiazepines are also highly addictive and the user may find themselves suffering severe 
withdrawal upon discontinuation of the drug. Both classes of drug can cause a rebound effect 
with termination of use, often causing insomnia that worse than it was to start with (Sateia & 
Nowell, 2004). As well as significant side effects, there are limited trials demonstrating the 
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efficacy of these medications in successfully treating insomnia long term (Krystal et al., 
2010). 
Benzodiazepines and benzodiazepine-like agents (the ‘Z’ drugs)  are the most widely 
used hypnotics (Touitou, 2007); however, their usefulness is limited to episodic insomnia of 
short duration (less than 4 weeks) as after this time their therapeutic effect wears off and with 
continued use, addiction can develop. They can cause serious adverse effects including 
daytime somnolence which increases the risk of road accidents and falls (Touitou, 2007). 
Once a patient has been treated with a sleeping medication, it can be difficult for them 
to terminate use. Benzodiazepine withdrawal symptoms have been well documented and can 
often last as long as 4 or 5 weeks following discontinuation (Rothenberg, 1997). Withdrawal 
effects appear to be related to the dose taken and the length of time that the hypnotic is taken 
for, therefore long term treatment of insomnia with hypnotics is not appropriate (Rothenberg, 
1997). Although the benzodiazepine-like “Z” drugs were once considered safer than 
benzodiazepines, the recent research has revealed similar negative effects (Brandt & 
Piechocki, 2013). 
While hypnotic medication may be useful for short term use in conjunction with non-
pharmacological interventions or to help break an acute cycle of sleeplessness and distress, 
behavioural strategies are more appropriate as long-term solutions (Rothenberg, 1997).  
Although the pharmacological approach to treatment has remained the most 
commonly used for decades, the widespread concern about long-term effectiveness, 
habituation, tolerance and the potential complications of these medications (Sateia & Nowell, 
2004) makes the search for other options most desirable. Given that insomnia is a distressing 
and debilitating condition, for which behavioural and cognitive therapies are not always 
funded or accessible, and psychopharmacological interventions are not safe as long term 
treatment options, it seems necessary to continue searching for safe, effective and accessible 
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treatment choices. One avenue that is worthy of exploration is the use of micronutrients as a 
treatment for insomnia. There is increasing scientific interest, both internationally and in NZ, 
in the use of complementary and alternative medicines (CAM) for the treatment of mental 
health conditions. In particular, micronutrient formulas have been receiving significant 
attention for their use in treating symptoms of psychiatric disorders, including bipolar 
disorder, anxiety, depression and ADHD. Even though almost 90 years of scientific literature 
is behind the importance of dietary nutrients for mental health (Kaplan et al. 2007), less is 
known about these micronutrient formulae than conventional medications.  
 
1.3 Association between Micronutrients and Mental Health 
It has long been known that nutrition plays an important part in mental health and 
wellness. As far back as antiquity this concept was recognised, demonstrated by Socrates 
famous quotation; “let food be thy medicine and medicine be thy food”. In 1910, the People’s 
Home Library, which provided in home medical guidance at a time in history when it was not 
always possible to visit the doctor, informed families that ‘insanity’ was in fact caused by 
inadequate or imperfect nutrition (Ritter, 1910). Although knowledge of the importance of 
nutrition in mental health dates back as far as the ancient Greeks, the introduction of 
psychiatric medications in the 1950’s brought about a shift in research and treatment focus, 
towards a preference for drug based treatments and interventions. Our current health systems 
reflect this shift towards medication and drug based treatments, and in so doing, has lost sight 
of much of the evidence surrounding the importance of nutrients for optimum brain health 
and function.  
Micronutrients, or vitamins and minerals, play an integral role in both physical and 
mental health. They are involved in many brain functions including the synthesis of 
neurotransmitters and the energy metabolism of nerve cells (Haller, 2005). They also play a 
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role in neuronal receptor binding of neurotransmitters, and help preserve the integrity of 
axons and their myelin sheaths (Haller, 2005). Although the brain accounts for only 2% of an 
adult’s entire body weight, it accounts for 20% of its resting metabolic rate. The human brain 
has a limited ability to store nutrients, and cannot decrease its need for energy when the 
supply of nutrition is limited, therefore it needs an almost continuous supply of energy 
brought to it through the blood-brain barrier. B-vitamins support this energy supply to the 
brain through the metabolism of glucose (Haller, 2005).  
Deficiencies in certain vitamins are known to be the cause of malfunction in the brain, 
and can result in a diverse range of neuropathology and neuropsychiatric symptoms (Bémeur, 
Montgomery, & Butterworth, 2011). They have the potential to cause changes in brain 
function and behaviour, and have even been found to influence personality and mood (Haller, 
2005). The most common deficiency disorders are those involving the group B vitamins 
which can result in disorders such as Korsakoff syndrome and pellagra (Kaplan, Crawford, 
Field, & Simpson, 2007). 
When we examine the complex role that each nutrient plays in integral brain 
functions, it makes sense that they have such on impact on our mental health and wellbeing. 
Kaplan and Colleagues (2007) provide a summary of the role each individual nutrient plays 
within brain processes. Vitamin B9 (folate) is involved in the synthesis of monoamine 
neurotransmitters and in serotonin and dopamine systems in the brain. It functions as a 
cofactor for enzymes that convert tryptophan into serotonin and can heighten serotonin 
function by slowing the destruction of brain tryptophan (Cousens, 2000). Vitamin B12 
(Cobalamin) is involved in the synthesis of many neurotransmitters, as well as assisting to 
maintain myelin sheaths on nerves resulting in healthy nerve conductance (Hutto, 1997). 
Vitamin B1 (Thiamine) assists with the synthesis of acetylcholine, GABA and glutamate 
(Bell et al., 1992). Vitamin B6  (Pyridoxine) plays a basic role in the production of many 
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neurotransmitters and a deficiency can result in a reduction of brain production of serotonin 
(Kaplan et al., 2007). 
Minerals also play an essential role in maintaining healthy brain function and mood. 
Calcium is an important cofactor for enzymes and assists with intracellular contact. An 
imbalance of calcium can result in anxiety, depression and cognitive dysfunction (Milne, 
2000). Chromium plays a role in the metabolism of glucose and lipids and this may be 
responsible for its role in mood (Milne, 2000) . Iron is essential for the production of 
adenosine triphosphate (ATP), the energy source of mitochondria. Magnesium also assists in 
the production of ATP through metabolising carbohydrates and fats, as well as these 
functions, it is essential for more than 300 biochemical reactions in the body, including 
maintaining normal nerve function. Zinc is involved in the structure and regulation of gene 
expression and is the co-factor for over 200 enzymes, playing a role in virtually all aspects of 
metabolism (Milne, 2000). Selenium is an essential trace mineral which forms part of 
antioxidant enzymes that help to protect cells from the effect of free radicals (Kaplan et al., 
2007). 
 
1.4 Effect of Single Nutrient Interventions on Psychiatric Symptoms 
Since the 1920’s, most research that has been conducted on micronutrients has 
investigated the effect of single nutrient treatments at a time on psychiatric symptoms. 
Research has found a wide range of benefits using B-vitamin supplementation to treat 
psychiatric symptoms.  In a case study where a patient was admitted to hospital with severe 
manic symptoms, complete normalisation of behaviour and mood was achieved after 
supplementation with vitamin B12, an effect that was maintained six months later with 
continued use of B12 (Goggans, 1984).  
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In a randomised controlled trial (RCT) conducted with patients with depression 
(n=24) or schizophrenia (n=17) deficient in folate, Godfrey et al. (1992) found that 
supplementation with 15mg  folic acid (vitamin B9) daily, resulted in clinically significant 
improvement in the treatment group when compared to placebo after three and six months of 
treatment, and these group differences increased with time. Another RCT of 127 adults with 
depression taking fluoxetine, found that supplementation with folic acid greatly improved the 
therapeutic effects of fluoxetine (Coppen & Bailey, 2000).  
Benton, Griffiths, and Haller (1997) conducted an RCT with 120 healthy female 
college students, and found that thiamine (vitamin B1) supplementation, when compared with 
placebo, was effective in improving mood, and that this effect was greater in those who had 
originally low level of thiamine. During the study, improvement in thiamine status was also 
associated with reports of feeling more “clearheaded, composed and energetic” (Benton et al., 
1997).   
In a case series of nine adults with schizophrenia and co-morbid depression, 
supplementation with pyridoxine (vitamin B6) was associated with markedly lower 
depression scores in two patients after four weeks of treatment (Shiloh, Weizman, Weizer, 
Dorfman-Etrog, & Munitz, 2001). A meta-analysis of nine RCT trials (n = 940) investigating 
the effect of pyridoxine on premenstrual syndrome in women found that supplementation 
with pyridoxine was more beneficial than placebo in reducing overall symptoms and 
particularly reduced symptoms of depression (Wyatt, Dimmock, Jones, & Shaughn O'Brien, 
1999).  
 Lecithin (a form of phosphatidylcholine) was found, in a small RCT (within-subject 
crossover, n=6) to produce greater symptom remission than placebo for five patients (Cohen, 
Lipinski, & Altesman, 1982). 
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Research had also examined the effect of individual minerals on mental health 
(Kaplan et al., 2007).  Thys-Jacobs, Starkey, Bernstein, and Tian (1998), found that in a RCT 
of 466 women with moderate to severe premenstrual syndrome, calcium carbonate reduced 
total symptoms by 48% compared with baseline, and was more beneficial than placebo. By 
the third month of treatment all four symptoms factors, negative affect, water retention, food 
cravings and pain, were significantly reduced.  
 Chromium, which plays an important role in the metabolism of glucose and lipids 
(Milne, 2000), has been used in several studies for its mood regulation properties. In a case 
series of five patients with dysthymic disorder, supplementation with chromium was found to 
produce symptom remission in all five patients (McLeod, Gaynes, & Golden, 1999). The 
authors subsequently conducted another case series, this time with eight patients with 
refractory mood disorders, and again found symptom remission in all patients (McLeod & 
Golden, 2000). In both studies, single-blind trials on several patients with alternative 
supplements confirmed the specificity of response to chromium. The authors hypothesise that 
the antidepressant effect of chromium may be due to its enhancement of insulin utilisation, 
which in turn increases the level of tryptophan available in the central nervous system 
(McLeod & Golden, 2000). An RCT (n = 15) of adults with atypical depression found that 
chromium produced significant symptom remission in 70% of the treatment group, compared 
with 0% in the placebo group (Davidson, Abraham, Connor, & McLeod, 2003). 
 Magnesium has been investigated as a therapy for the treatment of manic symptoms 
in bipolar disorder. Ten patients with severe and treatment-resistant mania were given 
intravenous magnesium sulphate in combination with their existing medications. Seven of the 
ten patients showed marked clinical improvement in symptoms, and doses of their current 
medications were able to be reduced after magnesium supplementation (Heiden et al., 1999). 
In an RCT of 20 adults with manic symptoms, magnesium was used in conjunction with 
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verapamil and compared to a placebo group who received verapamil and a placebo. 
Magnesium plus verapamil was found to produce significant improvement in manic 
symptoms, while placebo did not (Giannini, Nakoneczie, Melemis, Ventresco, & Condon, 
2000). In another study, nine female patients with rapid-cycling bipolar disorder were treated 
in an open label trial using either a magnesium compound or lithium for a period of up to 32 
weeks (Chouinard, Beauclair, Geiser, & Etienne, 1990). The magnesium was found to have 
clinical effects equivalent to lithium and seven of the nine patients showed a significant 
positive response.  
 Benton and Cook (1991) conducted an RCT with crossover design on 50 healthy 
adults. They found that supplementation with 100 mg selenium daily for five weeks was 
associated with significantly improved mood and was more effective than placebo. 
Historically, the trend in nutrient therapy has tended to examine or test a single 
nutrient for efficacy in treatment. This rationale closely follows the principle of the medical 
model; that one problem should be solved by one ingredient or drug, with some promising, 
albeit modest, results. However, as our bodies are complex systems where multiple chemical 
reactions involving a wide range of micronutrients are continuously occurring, it makes more 
sense physiologically for us as humans to use multi nutrient supplementation to address 
malfunctions (Mertz, 1994).   
Through the process of evolution we have come to require a wide range of nutrients in 
combination and in specific balance. With such complex brains it is important that we eat a 
varied diet to maximise the range of nutrients we are taking in. The way nutrients present 
naturally, in the form of food, combines several nutrients together, that often enhance each 
other, for example if calcium is taken with a small amount of magnesium and vitamin D the 
absorption is improved. In fact it is possible for treatments using single nutrients to cause an 
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imbalance and create deficiencies in other nutrients, for example if folate is ingested without 
vitamin B12 it can create a B12 deficiency in the body (Mertz, 1994). 
In the last decade, a significant shift has been made in the research that is being 
published in major medical journals indicating the importance of using complex multi-
nutrient formulas for treatment of mental health concerns. Where previously this multi-
nutrient therapy was thought of as “confounded” and imprecise research, attitudes are starting 
to shift as it becomes obvious that to treat issues in an organ as physiologically complex as 
the brain, it is more beneficial to use a broad-spectrum supplementation approach (Kaplan & 
Leung, 2011). Studies are increasingly using treatments containing multiple ingredients, 
containing between 6-36 different nutrients (Kaplan & Leung, 2011), this research will now 
be discussed. 
 
1.5 Effect of Combined Micronutrient Interventions on Psychiatric Symptoms 
 Recently micronutrients have been receiving increasing attention, both in New 
Zealand and internationally, as a treatment for supporting brain function and optimum mental 
health. During the 20th century, most nutrient interventions contained a single nutrient until 
the work of Bell et al. (1992), who found that a combination of vitamins B1, B2 and B6 
enhanced the therapeutic effect of tricyclic antidepressants, in a study of 14 geriatric patients 
suffering from depression.  
 During the 21st century, the number of studies using broad-spectrum 
micronutrient formulas has increased significantly, with many studies examining formulas 
containing between 6-36 ingredients (Kaplan & Leung, 2011). Due to the complex nature of 
the human brain and body, this move towards multi-nutrient formulas makes physiological 
sense. In 1994, Walter Mertz drew attention to the fact that the ‘one disease – one nutrient’ 
concept was out of date, and more recently Burford-Mason (2009) stated that to treat health 
18 
 
issues with one vitamin at a time “breaks the basic laws of physiology”. The author explains 
that no vitamin works alone, and instead works in conjunction with all the other vitamins, 
minerals, amino acids and essential fats.  Approximately 40 essential nutrients are required to 
regulate and repair body tissue and continue the innumerable bodily processes that maintain 
our health, and a deficiency in any one of these can cause illness (Burford-Mason, 2009).  
 
1.5.1 Depressed mood. Benton and colleagues (1995) explored the idea that 
supplementation with vitamins may influence mood. One hundred and twenty nine healthy 
adults took either a vitamin supplement containing nine vitamins, or a placebo, for one year. 
Female participants reported significantly improved mood at the end of 12 months, indicated 
by feeling “more agreeable”, more composed and reporting better mental health. Although 
there was no significant change in mood or mental health in the male participants, they also 
reported feeling “more agreeable” by the end of the study (Benton et al., 1995). 
Heseker et al. (1992) conducted an RCT with 1081 healthy men between the ages of 
17-29 years. At baseline, those men who had chronic nutrient deficiencies were found to have 
increased irritability, nervousness, depression and fear. For eight weeks, the participants were 
given a formula containing the recommended daily allowance (RDA) of vitamins B1, B2, B6, 
B9, B12, vitamin C and vitamin E. By the end of eight weeks, clinically significant 
improvements in mood were seen in those who had identified nutrient deficiency at baseline 
(Heseker et al., 1992). 
Harris and colleagues (2011) also investigated the association between mood and 
nutrient deficiency. They conducted an RCT of 50 healthy men between 50-69 years and 
supplemented the treatment group with a multi-nutrient formulation containing vitamins, 
minerals, antioxidants and herbal extracts. Compared with the placebo group there was a 
significant reduction in the overall score on a measure of depression, anxiety and stress, and 
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an improvement in alertness and overall daily functioning in the treatment group (Harris et 
al., 2011). 
In an RCT of 459 healthy Guatemalan women (aged 15-49 years), Nguyen and 
colleagues (2009) compared the impact of weekly versus daily combinations of micronutrient 
supplementation on depressed mood. The supplement formula used, which contained folic 
acid, iron, zinc and vitamin B12, was taken either daily or weekly (in varied doses) for a total 
of 12 weeks. At baseline 49.3% of the sample had depression scores above clinical cut-off, 
and by the end of the trial depression scores were lower in all treatment groups with a 
reduced total of 37.7% meeting clinical cut-off for depression (Nguyen et al., 2009). 
While the research discussed above involved non-clinical populations, the impact of 
multi-nutrient formulations on clinically unwell patients has also been researched. Gariballa 
and Forster (2007) conducted an RCT with 225 hospitalised acutely ill older patients where 
the treatment group received an oral nutritional supplement, designed to provide 100% of the 
reference nutrient intake of vitamins and mineral for a healthy older person. After six months 
of treatment, there were statistically significant reductions in depression ratings in the 
supplemented group and these were significantly more beneficial than placebo. 
In another RCT, selenium, vitamin C and folate were administered to 73 elderly 
patients in a nursing home to examine their effect on mood (Gosney, Hammond, Shenkin, & 
Allsup, 2008). Measures of anxiety and depression were taken at baseline, and again after 
eight weeks of micronutrient supplementation. At the conclusion of eight weeks, no 
significant effect on anxiety level was found, but for those patients who entered the trial 
depressed, there was a clinically significant reduction in depression scores for the 





1.5.2 Bipolar Disorder. All trials investigating the effect of micronutrient formulas 
on symptoms of bipolar disorder have been conducted using one product only, EMPowerplus 
(Truehope, AB, Canada). This micronutrient formula contains 36 ingredients; a mix of 
vitamins, minerals and amino acids. It has now become the most researched multi-ingredient 
formula on the market, with 25 current publications, and more under review (Rucklidge & 
Kaplan, 2013).  
Kaplan and Colleagues (2001) investigated the therapeutic benefit of EMPowerplus 
on symptoms of bipolar disorder in 11 adults. After six months of treatment, symptom 
reduction ranged from 55 – 66% on the treatment measures which included the Hamilton 
Rating Scale for Depression (HAM-D), the Young Mania Rating Scale (YMRS), and the 
Brief Psychiatric Rating Scale. The need for psychotropic medications also decreased by 
more than 50% for those who completed the six month trial.   
A year later, using the same micronutrient formula (EMPowerplus), Kaplan, 
Crawford, Gardner, and Farrelly (2002) examined the effect of the treatment on two 
medication free boys, who were eight and twelve years of age. The children were both 
deemed as having mood liability and explosive rage, and one of the boys had atypical 
obsessive-compulsive disorder while the other child had pervasive developmental delay. Both 
children benefitted from the micronutrient intervention. An ABAB design revealed that 
mood, angry outbursts and obsessional symptoms improved when initially treated with the 
supplement, returned when the children ceased taking the supplement, and again remitted 
upon reintroduction of the supplement (Kaplan et al., 2002).  
 Popper (2001) conducted an open label trial investigating the effect of EMPowerplus 
in 22 children and adults with bipolar disorder. The treatment resulted in clinical 
improvement in symptoms for 19 of the 22 patients, and of the 15 taking medication when 
starting the trial, 11 were stable on the nutrient formula only by the end of the trial.  
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In an open label trial using EMPowerplus to treat symptoms of bipolar disorder, 
Simmons (2003) found clinically significant improvements in 16 out of 19 adults taking the 
formula. Thirteen of the adults in the study, who had been taking medication prior to starting 
the nutrient formula, where able to remain stable while taking only the nutrients.  
In a database analysis of 358 adults with bipolar, it was found that treatment with 
EMPowerplus over a six month period, led to a 45% decrease in symptoms (Gately, 2009). A 
linear regression analysis revealed that symptom decrease was associated with a decrease in 
medications and an increase in dosage of the nutrient formula.  
Rucklidge, Gately, and Kaplan (2010) conducted a database analysis on 120 children 
and adolescents with bipolar taking EMPowerplus. After six months, a significant decrease in 
symptoms from baseline was evident, with 46% of the group showing a greater than 50% 
improvement. These improvements were found to be similar in those who had comorbid 
ADHD.  
In an open label trial by Frazier and colleagues (2012), ten children treated with 
EMPowerplus showed a decrease in symptoms of bipolar. Intent-to-treat analysis showed a 
37% decrease in depression scores and a 45% decrease in mania scores. The seven children 
who completed the full 6.5 months of the study demonstrated clinically significant decreases 
in scores of both depression and mania. 
 
1.5.3 Anxiety and Stress. Over the past decade there has been a number of trials 
examining the impact of high dose B vitamin formulas on stress and anxiety (Rucklidge & 
Kaplan, 2013). Five randomised controlled trials have been conducted using high dose B 
vitamin interventions, and all report treatment benefit. Carroll, Ring, Suter, and Willemsen 
(2000) examined the effect of a multivitamin and mineral supplement (Berocca) on 
psychological wellbeing in 80 healthy males. The double-blind randomised-control trial 
22 
 
found that relative to placebo, treatment with Berocca was associated with both consistent 
and statistically significant reductions in anxiety and perceived stress. Those in the treatment 
group also rated themselves as less tired and more able to concentrate by the end of the four 
week trial (Carroll et al., 2000). 
Schlebusch et al. (2000) conducted an RCT to assess the effects of a vitamin and 
mineral formula (Berocca Calmag) on stress in a sample of South Africans. Three hundred 
patients with predetermined high stress levels were recruited from two centres, and were 
randomly assigned to either a placebo or treatment group. After 30 days, both groups 
demonstrated significant reductions in all measures, but the treatment group showed greater 
reduction in all measures of stress, with this beneficial effect increasing throughout the day. 
In another RCT, Kennedy et al. (2010) assessed the effect of a high dose B-complex 
vitamin and mineral formula (Berocca®) on mood and cognition. Two hundred and fifteen 
healthy male adults completed measures of mood, stress, general health and cognitive 
performance, at baseline, and again after 33 days of treatment. The results showed that 
treatment with the multi-vitamin and mineral formula led to significant improvements in 
perceived stress, vigour, general health and cognitive performance compared with placebo 
group.  
Stough and colleagues (2011) examined the effect that a high dose vitamin B complex 
had on mood and psychological strain that was associated with chronic work stress. They 
conducted a three month long double-blind randomised controlled trial, in which sixty 
participants were assigned to a group receiving Blackmore’s executive B Active™, a group 
receiving a sustained release version of the vitamin B formula, or a placebo. No differences 
were found between the two treatment groups, and both treatment groups reported 
significantly lower personal strain and a reduction in confusion and depressed/dejected mood 
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after the 12 weeks compared with placebo. No effect was found of the treatment on state 
anxiety or depression measures. 
In an RCT, Rucklidge et al. (2012) compared two micronutrient formulas, Berocca™ 
and CNE™ (equivalent to EMPowerplus), to assess their impact on emotions and stress 
experienced after a 6.3 earthquake in Christchurch, New Zealand. Ninety one adults who 
were experiencing heightened anxiety or stress two to three months after the earthquake were 
randomised to receive Berocca™, CNE™ low dose, or CNE™ high dose for 28 days. During 
this time, they were monitored weekly using online questionnaires. All treatment groups were 
found to demonstrate significant declines in psychological symptoms, with the CNE™ 
treatment groups showing a greater reduction in intrusive thoughts compared with Berocca™. 
The CNE™ high dose group reported greater improvement in mood, anxiety and energy, 
with twice as many reporting “much” to “very much” improved, and were five times more 
likely to continue taking the formula after the trial than the Berocca™ group.  
In an open label trial by Gruenwald, Graubaum, and Harde (2002), the authors 
evaluated a probiotic multivitamin formula in 42 adults suffering from stress or exhaustion. 
The treatment was taken daily with breakfast for a total of 6 months, and was found to be 
associated with an overall 40.7% improvement in stress by the end of the trial. In addition to 
this, participants showed significant improvements in other areas related to stress, including 
decreased fatigue, a 29% decrease in occurrence of infections, and a decrease of 91% in 
gastrointestinal discomforts. 
In a recent study, researchers were struck with a very challenging situation, where a 
7.1 magnitude earthquake took place in the midst of a trial assessing a micronutrient 
treatment for Attention-Deficit-Hyperactivity Disorder (ADHD). This natural event presented 
a rare opportunity to investigate whether individuals with ADHD taking the nutrient 
supplement were more emotionally resilient post-earthquake than individuals with ADHD 
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who were not taking the supplement. Rucklidge, Johnstone, Harrison, and Boggis (2011) 
assessed 33 adults with ADHD using a measure of depression, anxiety and stress, pre-
earthquake, and again post-earthquake. Seventeen adults were not taking micronutrients at 
the time the earthquake occurred, and 16 were, creating a control group and a treatment 
group. At one week post-earthquake there were no significant between group differences; 
however, by two weeks post-earthquake, the treatment group reported significantly less 
anxiety and stress than the control group, and these differences could not be explained by 
other variables (Rucklidge, Johnstone, et al., 2011). 
 Long and Benton (2013) examined the effect of supplementation with multivitamins 
and minerals and/or docosahexaenoic acid (DHA) on laboratory-based measures of stress 
impulsivity and aggression. Using a double-blind randomised trial, 202 adult males with no 
history of impulsivity or aggression were treated with either a micronutrient formula 
(Centrum) and DHA, DHA and a placebo, Centrum and a placebo, or placebo and placebo. 
After 3 months it was demonstrated that those taking micronutrients had decreased perceived 
stress compared with other groups, but no significant change was found on measures of 
aggression or impulsivity. 
A case study of an 18 year old male with Obsessive Compulsive disorder (OCD) was 
conducted using the micronutrient formula EMPowerplus. Prior to the trial, the young man 
had undergone one year of cognitive behavioural therapy (CBT) which had reduced his OCD 
symptoms from a severe level to moderate. However, within a year his anxiety had increased 
back into the severe range and he had developed major depression. Rucklidge (2009) used an 
ABAB study design to examine the effect of the micronutrient formula on his OCD 
symptoms. After 8 weeks of taking EMPowerplus his mood had become stable, his anxiety 
was reduced and his obsessions were in remission. After discontinuation of the nutrients for 
an 8 week period his improvements regressed and his symptoms returned. With the 
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reintroduction of the formula it was found that again his symptoms improved (Rucklidge, 
2009). 
 
1.5.4 Attention Deficit Hyperactivity Disorder. In a study conducted by Harding, 
Judah, and Gant (2003), twenty children with attention deficit hyperactivity disorder (ADHD) 
were given either Methylphenidate (Ritalin) or a dietary supplements for  four weeks and 
their outcomes on neurocognitive tasks were compared. The dietary supplement contained a 
mix of vitamins, minerals phytonutrients, amino acids, essential fatty acids, phospholipids 
and probiotics, designed to treat ADHD biochemical risk factors. Both groups of children 
demonstrated significant improvements on the outcome measures, which were essentially 
identical in both groups, suggesting that the nutrient supplement was of equal efficacy in 
treating symptoms of ADHD as methylphenidate. 
In another study, the effect of the nutrient supplement, EMPowerplus, on children 
with psychiatric symptoms was explored. Kaplan, Fisher, Crawford, Field, and Kolb (2004) 
used an open label case series design, over 16 weeks, to examine the effect of the supplement 
on 11 children with mood and behaviour problems, including five children with ADHD. 
Significant improvement was found on seven out of eight Child Behaviour Checklist scales 
(CBCL), including measures of attention and significant improvement in mood.  
Rucklidge, Taylor, and Whitehead (2011) also explored the effect of the 
EMPowerplus micronutrient formula on symptoms of ADHD. They conducted an eight week 
open label trial where they gave the formula to 14 adults with both ADHD and severe mood 
dysregulation. Improvements across all outcome measures were found including measures of 
inattention and hyperactivity, impulsivity, depression, anxiety, stress and quality of life, all 
with medium to very large effect sizes. The study included a natural two month extension and 
at follow up, those who had continued to take the nutrient formula showed maintenance of 
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changes or increased improvements, while those who had stopped taking the nutrients had 
regressed towards baseline.  
 Most recently, a double-blind randomised controlled trial investigated the effect of 
supplementation with EMPowerplus nutrient formula 80 adults with ADHD. Rucklidge and 
colleagues (2014) randomised 80 adults into either a micronutrient or placebo group, where 
they received the intervention for a total of eight weeks. Intent-to-treat analysis demonstrated 
significant between-group differences favouring the micronutrient group on both self and 
observer ADHD rating scales. Although clinician rating scale results were not significantly 
different, they rated those in the micronutrient treatment group as more improved globally 
and on ADHD symptoms, than those taking placebo. Further, for those with moderate or 
severe depression scores at baseline, there was a greater improvement in mood in the nutrient 
group than placebo. 
 
1.5.5 Autism. Another area where micronutrient interventions have shown promising 
preliminary results is in the area of autistic spectrum disorders. Adams and Holloway (2004) 
conducted a randomised, double blind placebo controlled trial, where they investigated the 
effect of a vitamin and mineral supplement on children with autistic spectrum disorder 
(ASD). The supplement was a liquid suspension called Spectrum Support™ II, and contained 
15 vitamins, 11 minerals and 3 amino acids. 20 children with ASD, between the ages of three 
and eight years, were randomised into either an active or placebo group, and received their 
assigned intervention for a total of three months. Using a global, parent-rated scale, the study 
found significant group differences in measures of sleep and gastrointestinal problems, in 
favour of the nutrient intervention.  
Another study, conducted by L. Mehl-Madrona, B. Leung, C. Kennedy, S. Paul, and 
B. J. Kaplan (2010), was interested in the self-injurious behaviour (SIB), aggression and 
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tantrums that often accompany ASD. The study used the naturally occurring situation of 
some parent’s preference for a non-pharmaceutical approach, and treated this group of 44 
children with the EMPowerplus micronutrient formula. This group was matched with 44 
similar children whose families had selected conventional treatments who formed the 
medication group. During the trial, both groups significantly improved on the Childhood 
Autism Rating Scale and the Childhood Psychiatric Rating Scale, as well as showing 
significant decreases in total Aberrant Behaviour Checklist scores, with the micronutrient 
group showing a significantly greater improvement on this scale than the medication group. 
Compared with medication, the intensity of SIB was found to be lower in the micronutrient 
group by the end of the study, and improvement on the Clinical Global Impressions scale was 
higher. Other advantages noted for treatment by micronutrient compared with medication 
were: lower activity level, less social withdrawal, less anger, better spontaneity with the 
examiner, less irritability, lower intensity SIB, markedly fewer adverse events and less 
weight gain. In contrast, the advantages of medication intervention were recorded as being 
covered by insurance, fewer pills and less frequent dosing.  
Adams and colleagues (2011) examined the effect of a mineral and vitamin 
formulation (Syndion™) in adults and children with autism. A randomised, double-blind, 
placebo controlled trial was conducted over a three month period where 141 participants were 
administered either the nutrient supplement or a placebo, and pre and post symptoms of 
autism were measured. During the trial, blood results of those in the supplement group 
showed an improvement in the levels of many vitamins, minerals and biomarkers towards 
normal levels. This group showed significantly greater improvements than placebo on the 
Parental Global Impressions-Revised (PGI-R), as well as on measures of hyperactivity, 
tantrums and receptive language. Regression analysis indicated that degree of improvement 
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on the PGI-R was strongly associated with several biomarkers, with biotin and vitamin K 




A review of this micronutrient literature suggests that mood disorders, anxiety, stress, 
ADHD and autistic spectrum disorder can, in some cases, be managed with a mixture of 
biologically active minerals and vitamins, without the use of other traditional 
psychopharmacological interventions. Positive results have been reported in over 25 
publications, in multiple settings, with many types of designs and analysis, adding further 
support to the notion that micronutrients may influence mental health function.  
This study plans to extend the use of micronutrients in its treatment of psychiatric 
symptoms, to decipher if it also has a positive effect on the symptoms of insomnia. As such, 
this is a pilot trial to determine whether there is indeed an effect, and if a broad spectrum 
multi-nutrient formula, EMPowerplus, is associated with improved sleep pattern and quality 
compared with a no treatment baseline period. Due to previous research demonstrating a 
reduction in stress, anxiety and ruminative thinking from micronutrient supplementation, and 
anecdotal reports of improved sleep quality, it is hypothesised that treatment with the 
micronutrient supplement will lead to a reduction in insomnia symptom severity, and a 
decrease in depression, anxiety and stress scores. 
The effect of the nutrient formula on symptom severity, sleep onset, sleep length, 
night waking, sleep efficiency and subjective feeling of restedness, will be assessed using 
single case methodology. As this is a pilot study, it does not require large numbers of 
participants, its main objective is to detect if there is indeed an effect of micronutrients on 
insomnia symptoms. This will be established by taking multiple baseline measures of the 




It is hypothesised that thus study will find the following: 
1. The micronutrient intervention will be associated with improvements in 
insomnia symptom severity as measured by the Pittsburgh Insomnia Rating 
Scale. 
2. The micronutrient intervention will be associated with improvements in sleep 
onset latency, frequency of night waking, total sleep duration, sleep efficiency, 
and subjective feeling of restedness as reported in daily sleep diaries. 
3. The micronutrient intervention will be associated with improvements in 
depression, anxiety and stress, as measured by the DASS. 
4. Improvements will be maintained over a three month follow-up period for 





















Participants were recruited in Christchurch, New Zealand, between January 2013 and 
November 2013 using advertising on The University of Canterbury campus, internet health 
forums, and through community health services. From 51 people who completed the 
screening questionnaire, 14 adults with symptoms of insomnia participated in the current 
study. Of the 51 people who fully completed the online screening questionnaire, 20 met the 
required cut-off, meaning their insomnia symptoms were severe enough to allow them to 
participate in the study (see inclusion criteria). All people who completed the screening 
questionnaire who did not meet criteria for the study were sent a link to a list of sleep support 
services in the Canterbury area. Every person who met the screening cut-off and all other 
eligibility criteria was contacted via email and offered an appointment to discuss 
participation.  
Three people who completed online screening and were eligible for the study did not 
reply to the offer of participation. Two participants who attended the initial baseline 
appointments withdrew from the study before treatment had commenced due to external life 
stressors and an inability to commit to the time frame of the study. One participant was 
excluded from the study during baseline phase due to exclusion criteria. 
All study procedures were approved by the Human Ethics Committee at the 
University of Canterbury. The trial was registered retrospectively with the Australian New 
Zealand Clinical Trials Registry (ACTRN12613000364774). 
 
2.1.1 Inclusion and Exclusion Criteria. To be invited to participate in the trial, 
participants were firstly required to meet diagnostic criteria for insomnia as measured by the 
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Pittsburgh Insomnia Symptom Questionnaire (PISQ). Secondly the severity of their insomnia 
was measured using the Pittsburgh Insomnia Rating Scale (PIRS) and this score was used to 
determine eligibility for participation in the trial. 
The Pittsburgh Insomnia Rating Scale (PIRS) is a 65 item self- report scale, used to 
measure severity of insomnia in clinical trials (Moul DE., 2002), and which may be 
particularly useful for tracking the impact of an intervention (Veqar Zubia, 2014). 
Interpretations of total scores on the PIRS state that a total score of 0 (lowest possible score) 
is “good”, and a total score of 195 (highest possible score) is “bad” (Moul DE., 2002; Veqar 
Zubia, 2014). As no further indication is given in the literature as to a suggested clinical cut-
off for the 65 item scale, the Likert scale used within the measure was used as an indication 
to interpret total scores. The PIRS uses a 4 point Likert scale to rate each of 65 questions 
about symptoms of insomnia; with 0 indicating “not at all bothered”, 1 indicating ”slightly 
bothered”, 2 indicating “moderately bothered” and 3  indicating “severely bothered”. These 
ratings were used to determine overall total scores corresponding to those not affected by 
insomnia symptoms, those slightly affected by insomnia symptoms, those moderately 
affected by insomnia symptoms, and those severely insomnia symptoms. In order to 
investigate whether the treatment intervention (micronutrients) did indeed have an impact, a 
conservative cut-off score was chosen at the mid-point between “slight” insomnia symptoms 
(total score = 65) and “moderate” insomnia symptoms (total score = 130). This mid-point fell 
at 97.5 and therefore it was determined that participants would have to meet a total PIRS 
score of 98 or above to be affected by symptoms of insomnia to the degree required to 
measure impact of the intervention in the trial.  Only those with a PIRS total score of 98 or 
above at screening were invited to participate in the study. Participants were not required to 
have a pre-existing diagnosis of insomnia, and were not excluded for having a comorbid 
psychiatric diagnosis. Only those who were not currently taking a psychiatric or sleep 
32 
 
medication, or who had been medication free for at least 4 weeks, were considered for the 
trial. 
Other inclusion criteria included: 
1) Participants had to be over 18 years of age 
2) Participants had to be able to travel to the University Campus for four appointments 
during the trial 
3) Participants had to be able to swallow six capsules per day as well as complete the daily 
and weekly measures required 
 
Other exclusion criteria included: 
1) Any participant with sleep apnoea 
2) Any participant who was pregnant or breastfeeding 
3) Any individual with a child under two years of age 
4) Any participant with a neurological disorder involving brain or other central   function 
(e.g. MS, narcolepsy, epilepsy) 
5) Any participant with a serious medical condition for which major medical intervention 
was anticipated during the trial 
6) Participants who took an oral antibiotic in the previous six weeks were excluded 
temporarily. 
7) Any participant judged clinically to be at serious risk for suicide or violence in the 
opinion of the researchers. 
 
These criteria resulted in the exclusion of one participant during the baseline phase as 
mentioned previously. This participant was clinically judged by the researchers to be at 
33 
 
serious risk for suicide and was referred to the University Health Centre to be clinically 
assessed. 
2.1.2 Final Sample. Of the 14 adults who participated in the study, 12 participants 
completed the entire trial. One participant chose to drop out of the study after four weeks of 
treatment due to no perceived benefit. Another participant dropped out after three days of 
treatment due to experiencing side effects. Due to reported life stressors, two of the twelve 
participants who completed the entire trial, failed to consistently complete measures 
throughout the trial making analysis of their results on some measures invalid. Figure 1 
provides a visual diagram of the flow of participants in and out of the study. The mean age of 
participants at data collection was 36.64 (SD = 13.24, range 21–58). Twelve participants 
identified as being of New Zealand European ethnicity, one identified as being of Indian 
ethnicity and one as “other”. The most common category for occupation status of participants 
was: student (nine participants), the other occupations listed where: learning skills advisor, 





Figure 1. Consort Flow Diagram. 
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o PIRS and DASS (n=2)





o Sleep Diary (n=5)
o PIRS and DASS (n=4)
Not enrolled (n=34)
o Did not meet inclusion critera (n=31)




2.2.1 Measurements of Demographic Variables.  History questionnaire. This 
questionnaire was used to assess demographic variables including the participant’s ethnicity, 
occupation, household income, physical health, psychiatric health, previous or current 
medication, antibiotic use history and other important medical information. 
 
2.2.2 Self-rated Dependent Measures. Pittsburgh Insomnia Symptom Questionnaire 
(PISQ) The PISQ is a 13-item self-report instrument designed to establish a clinically 
relevant case definition of insomnia, that is consistent with widely used insomnia criteria 
(Okun et al., 2009). PISQ questions are based on the American Psychiatric Association's 
fourth edition of the Diagnostic and Statistical Manual-IV criteria (American Psychiatric 
Association, 2013) for primary insomnia, and are consistent with the American Academy of 
Sleep Medicine's Research Diagnostic Criteria.  PISQ items contain multiple choices on an 
ordinal scale which assess the presence, frequency and severity of the complaint. For 
example, a question “During the past month have you had difficulty falling asleep?” includes 
choices ranging from 0 = never to 5 = always. In an assessment of the psychometric 
properties of the PISQ it was found to identify 9.8% of the sample as meeting criteria for 
insomnia which is a number consistent with established diagnostic rates (Okun et al., 2009). 
Reliability of the scale was established with Cronbach’s α (α = 0.89), and the scale had a high 
specificity (> 90%) (Okun et al., 2009). 
Pittsburgh Insomnia Rating Scale (PIRS). The PIRS is a 65 item self-report 
instrument designed to assess severity of insomnia. The scale is widely used in clinical 
practice (Veqar Zubia, 2014), and findings suggest that PIRS has excellent internal 
consistency, test-retest reliability and good validity (Moul DE., 2002; Veqar Zubia, 2014). 
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Answers are indicated on a 4-point Likert scale; 0 = “Not at all bothered”, 1 = “Slightly 
bothered”, 2 = “Moderately bothered”, 3 = “Severely bothered”, and Scores can range from 0 
to 195. For the purpose of this study a cut-off point for severity was set at the mid-point 
between “slight” insomnia symptoms (total score 65) and “moderate” insomnia symptoms 
(total score 130) resulting in a cut off score of 98  to have insomnia symptoms deemed severe 
enough to participate in the study. The test- retest reliability of the PISQ has been found to be 
good (r=0.90) (Moul DE., 2002) and internal consistency was found to be excellent; 
Cronbach’s α (α = 0.93) (Veqar Zubia, 2014). 
Depression Anxiety and Stress Scale (DASS). The DASS is a 42 item questionnaire 
consisting of 3 self-report scales designed to measure negative emotional states of depression 
anxiety and stress (Lovibond & Lovibond, 1995). The scale uses “over the past week” 
questions to measure current symptoms of depression, anxiety and stress. The anxiety 
subscale shows good correlation of 0.81 with the Beck Anxiety Inventory and the depression 
subscale shows moderate correlation of 0.74 with the Beck Depression Inventory (Lovibond 
& Lovibond, 1995). Internal consistency has been found to be favourable with Cronbach’s α 
= 0.96, 0.89 and 0.93 for depression, anxiety and stress respectively (Brown, Chorpita, 
Korotitsch, & Barlow, 1997). 
The Expanded Consensus Sleep Diary for morning (CSD-M). The CSD-M is an 
expanded version of the Consensus sleep diary, an original collaboration by insomnia experts 
and potential users, to create a standard sleep diary for insomnia aiming to facilitate accurate 
comparisons across studies. The CSD-M includes additional items about early morning 
awakenings, estimated total time asleep, Likert scale rating for refreshing quality of sleep, 




2.3 Design and Procedures 
Participants who were interested in the study first completed an online screening 
process from which eligible participants were invited to participate in the study. The study 
followed a multiple baseline design, whereby participants were randomly assigned to a 
baseline phase of one, two or three weeks, followed by an eight week treatment phase. 
During both baseline and treatment phases, daily sleep diaries were completed by the 
participants, as well as weekly online questionnaires consisting of the PIRS and DASS. 
 During the intervention phase participants visited the University of Canterbury to 
meet with the researcher at both four weeks, and eight weeks of intervention. The follow up 
phase of the study involved each participant completing the PIRS and DASS online, three 
months after completing the treatment phase. All participants were monitored by a clinical 
psychology student under the supervision of a registered Clinical Psychologist. 
2.3.1 Screening Phase. Individuals who were interested in the trial visited the link 
provided on the advertisements which guided them to the Mental Health and Nutrition 
Research Group’s website, www.menthalhealthandnutrition.co.nz. Here they completed the 
online screening questionnaire which determined eligibility for the study. Those who did not 
meet criteria for the study were emailed by the researcher with an explanation as to why they 
were excluded, and were provided with a link (also through the Mental Health and Nutrition 
website) to a list of sleep support services within the Canterbury area. Those who met the 
criteria for participation in the study were emailed and invited to meet with the researcher at 
the University of Canterbury to further discuss the study and participation. 
During the initial appointment each participant was provided with a detailed 
information sheet explaining the study. Copies of the information sheet and consent form 
provided at this meeting can be found in Appendix A. The study was verbally explained in 
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detail to each participant including the aims, limitations of confidentiality and requirements 
of participating in the study, and participants were given ample opportunity to discuss and 
ask questions about any aspect of the study they wished. Participants were informed that 
participation in the study was entirely voluntary and that at any time they could withdraw 
from the trial, without any negative impact on their future health care. Participants were 
offered the option of taking time to consider participation before contacting the researcher at 
a later date. Informed consent was obtained from the participant. 
2.3.2 Baseline Phase. After consent was obtained, each participant was assigned an 
identification number in consecutive order from 1 to 14 depending on the order in which they 
entered the study. They were also asked to open an envelope containing their baseline length. 
Baseline lengths had previously been randomly assigned to identification numbers and the 
researcher was blinded as to what they were. Daily sleep diaries of adequate length for the 
participants baseline phase were given along with instructions for completing the diary. 
Participants were also informed that the online questionnaire would be emailed to the 
participant to complete at the end of each week of participation. A copy of the daily sleep 
diary, with instructions, can be found in Appendix B. A second appointment was made for 
the participant to meet with the researcher at the end of their assigned baseline phase to pick 
up further sleep diaries and collect the micronutrient capsules. At each visit to the University 
the participant was provided with a $10 petrol voucher to compensate travelling costs. 
After completing their baseline phase, each participant met again with the researcher 
to hand in their completed baseline sleep diaries, and collect enough new sleep diaries and 
micronutrient capsules for the first four weeks of intervention. Participants were instructed to 
take three capsules with breakfast and three capsules with lunch to avoid side effects and 
minimise the risk of an energising effect too late in the day. The participant was advised to 
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contact the researcher immediately if they experienced any adverse side effects from the 
micronutrients. 
2.3.3 Intervention Phase. Daily Self Defense (DSD) is a newer version of 
EMPowerplus (EMP+), a broad spectrum micronutrient formula containing 16 minerals, 14 
vitamins, 3 amino acids and 3 antioxidants. An ingredient list for DSD can be found in 
Appendix C. Participants took six capsules daily during the study, often dividing the dose 
into two, three capsule doses. They were informed of the importance of taking the nutrients 
with plenty of food and water to minimise any side effects. DSD was provided to the 
participants free of cost for the duration of the study, and if participants wished to continue 
taking the supplement during the follow up period they were provided with another bottle. 
Participants were also provided with contact details for purchasing the product within New 
Zealand if they wished to continue using the supplement after completion of the trial. 
Participants were seen at four weeks and eight weeks after final baseline appointment. 
At the four week appointment, the first four weeks of daily sleep diaries was collected and 
the participant was provided with the second four weeks’ worth of diaries, as well as a second 
bottle of micronutrients (enough for the remaining four weeks). They were given a chance to 
discuss the trial with the researcher and were asked about any changes they had noticed. 
Participants also completed weekly questionnaires throughout the treatment phase which 
asked about side effects and changes in mental health or insomnia symptoms.  
At eight weeks of treatment participants finished the trial. During this appointment the 
daily sleep diaries were collected, and the participants were asked how they felt the 
micronutrients had gone for them, and if they had noticed any changes. The participant was 
thanked for their involvement in the study and reminded that the researcher would be in 
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contact in approximately three months’ time to send them an online follow-up questionnaire 
to review their mental health and sleep symptoms. 
 
2.3.4 Follow- up Phase. Approximately three months after completing the 
intervention phase participants were emailed an online follow up questionnaire to complete. 
This questionnaire included the DASS and PIRS as well as asking whether the participant 
was still taking the nutrient formula and reasons why they did or did not chose to continue. 
 
2.4 Statistical Analysis 
The primary outcome measures were the PIRS and the Consensus daily sleep dairy. 
The PIRS provides information about the severity of a broad range of insomnia symptoms, 
while the daily sleep diary provides measures of sleep onset latency, frequency of night 
waking, total sleep duration, sleep efficiency, and feeling of restedness upon waking. 
Individual changes across baseline and intervention phases are presented for the daily sleep 
diary variables using time series graphs, and Percentage Exceeding the Median ( PEM), is 
used to describe effect size (Ma, 2006). Modified Brinley plots are used to analyse individual 
changes over time for the PIRS and then for the secondary outcome measures (Depression, 
Anxiety, and Stress scores from DASS). Reliable Change is calculated for each measure 








The results of the intervention, assessed using the primary and secondary outcome 
measures, are presented in the following sections. Primary outcome measures included data 
from the daily sleep diaries and the PIRS, while secondary outcome measures include the 
DASS data. Individual changes across baseline and intervention phases, as reported in daily 
sleep diaries, are presented first, using time series graphs1 following the conventions of the 
multiple-baseline design. Modified Brinley plots were used in multiple-baseline format to 
analyze individual changes in the primary PIRS measure. Modified Brinley plots were also 
used to analyse changes over time in Depression, Anxiety, and Stress scores (DASS) and to 
summarise the outcomes of the study across several measures.  
Demographic characteristics of the final sample are presented in Table 1 below. 
 
Table 1: Demographic Characteristics of Final Sample 
Characteristic Number Mean Standard 
deviation 
Percentage 
Sex     
      Male 2   14 
      Female 12   86 
Age in years (mean)  37.64 13.24  
Ethnic group     
       NZ European 12   86 
       Indian 1   7 
       Other 1   7 
 
 
                                                          
1 All graphs created using Sigma Plot 12.5 (Systat Software Inc.) 
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3.1 Safety and Adherence 
The adverse effects that were reported by participants during the study were mild and 
transitory, and were able to be remedied by reducing the dose of capsules, or by simply 
waiting until the symptoms passed without any explicit action. This was true for all but one 
participant, who decided to withdraw from participation in the study due to side effects, as 
shown in Figure 1. 
Four out of fourteen (29%) participants experienced side effects which may have been 
related to the intervention. One participant experienced a mild stomach upset for the first few 
days of taking the capsules which then ceased. One participant reported a very dry mouth at 
the beginning of the fourth week of taking the capsules which ceased by the end of the week. 
Another participant reported experiencing an increase in intensity of sensations such as sights 
and sounds during the seventh week of taking the capsules, which was remedied by reducing 
the dose to three capsules per day. A fourth participant reported headache, reflux, mild 
nausea and dizziness after starting the intervention. This participant decided to withdraw 
from the study during the first week of taking the capsules due to the side effects experienced 
(Refer to Figure 1). 
Table 2: Treatment-emergent Adverse Effects Reported by Participants 





None. Symptoms passed 
on their own 




None. Symptoms passed 
on their own 




Reduced dose to 3 








Participant chose to 





Of the thirteen participants who continued with the intervention phase, all (100%) 
were compliant in terms of adherence to the treatment protocol. This involved taking the 
recommended micronutrient dose (six capsules) daily, without missing a significant number 
of doses, which was defined as a compliance rate of greater than 80%, or no more than 67 
missed capsules across the intervention phase. Of the thirteen compliant participants, eight 
reported perfect compliance, two participants reported a total of three missed capsules, one 
reported a total of 27 missed capsules, and one participant reported a total of 30 missed 
capsules. 
3.3 Sleep Diary data: Time Series Multiple-baseline Analysis 
In this section, data from the sleep diaries is presented as time series graphs following 
the conventions for the multiple-baseline design. Data from Participants 5 and 12 are not 
included in these graphs as Participant 5 withdrew participation in the study during the first 
week of intervention, and Participant 12 did not complete their daily sleep diaries. On each 
graph the middle or median value from baseline phase has been extended to form a median 
line through the intervention phase, and the percentage of intervention data points exceeding 
the median (in direction of desired change) is noted.   This  Percentage Exceeding the Median 
( PEM), is used to describe effect size in single-case research (Ma, 2006). A PEM in the 
range of 70-90% is reported to indicate a moderate treatment effect, while a PEM >90% 
indicates a large treatment effect (Ma, 2009).  
Information from the sleep diaries was used to calculate each participant’s  nightly 




) x100), and subjective feeling of restedness on waking. These data are 
presented in a multiple-baseline across-participants format in Figures 2 to 6.  
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Sleep-onset latency: Figure 2 presents sleep-onset latency measured in minutes. In 
Baseline, Participants 7 and 14 showed no evidence of difficulty initiating sleep and therefore 
it was not possible to detect a treatment effect with this measure. The other participants all 
reported some degree of delayed sleep onset. Note that the criterion for clinical severity of 
sleep onset latency is 30 minutes or more, occurring on three nights per week (American 
Psychiatric Association, 2000). Against this criterion, Participant 6 showed only marginal 
difficulty with sleep onset on some nights, but all remaining participants met this criterion, 
showing evidence of difficulty with sleep onset. Notably, Participants 3 and 4 had no nights 
during baseline where sleep onset was less than 30 minutes. Participants 1, 2, 3, 4, 6, 8, 10, 
and 13 all show relatively stable or increasing (worsening) patterns of sleep onset latency 
during baseline, while Participants 9 and 11 showed some improvement during this phase, 
which reduces the ability to detect a treatment effect for these cases. 
When the intervention began, sleep onset latencies for Participants 1, 2 and 3 
immediately decreased and continued to improve across the intervention phase, with each 
participant showing a percentage of data points exceeding the baseline median (PEM) of 
95%, 93% and 100% respectively, indicative of a large effect size. A delayed treatment effect 
can be seen for Participants 4 and 9; with both showing a fairly stable pattern of sleep onset 
scores of 30 minutes or less in the final two weeks of intervention. Despite this delay in 
response, Participant 9’s PEM still showed a large effect size; however, Participant 4’s PEM 
was 64%, reflecting the delay in treatment effect.  
Participant 8 and Participant 11 show a small treatment effect evident in the reduction 
















































































































































































Figure 2: Times series of each participant’s nightly sleep onset latency (in minutes) as 
reported in daily sleep diaries. The horizontal line shows the baseline median and the 







 Frequency of night waking: The DSM-IV(American Psychiatric Association, 2000) 
criteria for insomnia  define a difficulty maintaining sleep, or “multiple night wakings”, as 
waking three or more times per night, at least three nights per week. Against this criterion, 
Participants 3, 4, 9, 10, 13, and 14 show evidence of difficulty with night waking (Figure 3).  
While the remaining participants all reported some degree of night waking, they did not meet 
criterion for this particular sleep difficulty. It must be noted that for these participants their 
problem may have been in their inability to initiate sleep once woken, rather than the 
frequency of night waking per se. The majority of participants showed stable or worsening 
(increasing) patterns of waking during baseline, while Participant 10 showed some 
improvement during this phase, which reduces the ability to determine a treatment effect for 
this case.   
 When the intervention began, waking frequency for Participants 2, 7, and 14 
immediately decreased, and they maintained this improvement across the intervention phase, 
reflected in PEM effect sizes of 93%, 98% and 82% respectively.  Participants 3, 6, and 9 
showed a delayed pattern of responding to the intervention, with frequency of waking 
reducing more obviously after four weeks of treatment. Despite this delay, Participant 3’s 
PEM (98%) still indicated a large effect size, and Participant 6 and 9’s PEM indicated a 
moderate effect size (70% and 78% respectively).  Participants 1, 4 and 13 showed evidence 
of a slight treatment effect towards the end of the intervention phase with a slight reduction in 


































































































































































































Figure 3: Time series of each participant’s frequency of night waking as measured by 




Total time asleep: Sleep duration is reported in Figure 4 as a percentage of 8 hours to 
most succinctly capture the wide range of data for this measure and to clearly display each 
person’s deviation from the 8-hour ideal. In baseline, all participants, with the exception of 
Participant 2, had total nightly sleep of less than 8 hours on the majority of nights. 
Participants 1, 3, 6, 8, 10 and 14 showed fairly stable patterns of total sleep; with most 
participants reporting a median sleep durations of approximately 80% of 8 hours total sleep 
(i.e., 6.4 hours). Participants 9 and 13 showed some improvement during baseline phase 
which reduces the ability to determine a treatment effect for these cases. Participants 2, 4 and 
11 showed large variability in baseline scores with no clear trend.  
The treatment effect can be discussed in two ways for this set of graphs, firstly 
through comparing each participant’s percentage of nights per week, with a total sleep time 
of 8 hours of more (during both baseline with intervention phase), and secondly by 
examining their  median hours asleep in baseline and then in the treatment phase. The PEM 
effect size is also considered for each participant irrespective of their baseline median being 
below, at or above 8 hours of sleep.   
When the intervention began, total time asleep for Participants 1, 3, 4, 7, 9, and 14 
immediately increased and continued to improve across the remainder of the intervention 
phase. Participant 1 had 0% of nights per week with a total of eight hours or more sleep 
during baseline, which increased to 32% of nights per week during intervention, and a PEM 
of 82% indicated a moderate effect size. Participant 3 also had 0% nights of eight hours or 
more total sleep during baseline, and this increased to 27% of nights per week during 
intervention, and a PEM of 94% indicating a large effect. Participant 4 had a total sleep time 
of ≥8hours on 24% of nights per week during baseline, which increased to 52% of nights per 
week during intervention, and a PEM of 88% indicating a moderate effect. Participant 7 slept 
for ≥8hours on 33% of nights during baseline, which increased to 91% of nights during 
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intervention, reflected in a large effect size (PEM = 93%). Participant 9 had a total sleep time 
of ≥8hours on 29% of nights during baseline, which rose to 59% per week during 
intervention, and a PEM of 96% indicated a large treatment effect. Participant 14 had 0% of 
nights where they slept for ≥8hrs during baseline, which increased to 61% of nights during 
intervention, and a PEM of 100% indicating a large effect. 
Participants 6 and 10 showed a delayed treatment effect that became more evident in 
the second half of the intervention. Participant 6 was getting ≥8hours sleep on 29% of nights 
during baseline and this improved to 50% of nights in intervention. Participant 10 was getting 
0% of ≥8hours sleep during baseline, which increased to 30% of nights per week in 
intervention. Both Participants showed a moderate treatment effect with a PEM of 82% and 
73% respectively. 
 Participant 8 appears to show two phases of response during intervention; firstly 
there appears to be an immediate treatment effect that lasted the first 4 weeks, which is 
followed by an increased variability in scores and disappearance of a treatment effect during 
the second four weeks of treatment.  
Participant 11 showed a small treatment effect through the reduction of very short 



































































































































































Figure 4: Time series of each participant’s total nightly sleep duration as measured by 
daily sleep diaries. Numbers on the graphs report the value of data points that are off-




Sleep efficiency: A sleep efficiency score below 85% is thought to indicate 
problematic or abnormal sleep (A. J. S. Spielman, P; Thorpy, M.J, 1987). Against this 
criterion all participants, except 1, 2 and 6, showed a baseline median efficiency score that 
was in the clinical range (Figure 5). Participants 1, 2, 3, 4, 8, 10, 11, and 14 showed stable or 
worsening patterns of sleep efficiency during baseline, while Participants 7, 9, and 13 showed 
some evidence of improvement which may affect the ability to determine a treatment effect 
for these cases.  
When intervention began Participants 1, 2, 3, 4, 7, 9, and 14 showed an immediate 
increase in sleep efficiency scores and this improvement was maintained or continued to 
increase across the rest of the intervention phase. PEM scores indicate that all of these 
participants showed a large effect size with the exception of Participant 2 who showed a 
moderate effect size.  
Participant 6 showed a moderate treatment effect (PEM 80%) even though baseline 
scores already showed sleep efficiency above 85%.  Participant 10 showed a moderate 
treatment effect (PEM 86%) and a general trend of improvement with some outlying low 
scores, and Participant 11 showed some reduction in variability of scores. Participants 13 and 
8 showed no evidence of a treatment effect, and in fact Participant 8 appeared to be getting 
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Figure 5: Time series of each participant’s nightly sleep efficiency score as measured by 
daily sleep diaries. Numbers on the graphs report data points that are off the scale. 




Subjective feeling of restedness: The majority of participants showed stable or 
worsening (decreasing) patterns of restedness during baseline, although Participant 2 was 
missing some baseline data which makes accurate interpretation of this phase difficult (Figure 
6). Participant 7 showed some improvement during baseline which reduces the ability to 
determine a treatment effect for this case.  
When intervention began, Participants 1, 2, 6, 7 and 14 showed an immediate 
improvement in feelings of restedness which were sustained or continued to improve for the 
remainder of the intervention. PEM scores indicate that Participants 1, 2 and 7 had a 
moderate effect size, while Participants 6 and 14 had a large effect. 
Participants 3 and 9 showed a delayed treatment effect which became evident by 
week 4 of the intervention, and while Participant 9’s PEM still indicated a moderate effect 
size, the delay in treatment effect means that the PEM does not reflect this for Participant 3. 
Participants 4 and 10 showed small treatment effects with an increased number of higher 



























































































































































































Figure 6: Time series of each participant’s daily feeling of restedness upon waking as 





3.3.1 Summary of Time Series Data. In summary, six participants (Participants 1, 2, 
3, 6, 7, and 14) showed a moderate or large treatment effect on four out of the five nightly 
variables measured, while Participant 9 showed a moderate or large treatment effect on all 
five variables. Participants 4, 8 and 10 showed moderate or large treatment effect in some of 
the variables, and Participants 11 and 13 showed no treatment effect on any variable. 
 
Table 3. Summary of Effect Sizes using PEM for Sleep Diary Data 
Variable 










1      
2      
3      
4      
6      
7      
8      
9      
10      
11      
13      
14      
 
Effect Size using PEM: 
Small or none = Blank 
Moderate =  
Large =  
 
3.4 Change over Time in Insomnia, Depression, Anxiety, and Stress 
The following sections will present data for the ten participants who completed PIRS 
and DASS measures throughout the intervention phase, using modified Brinley plots 
(Blampied, 2007, 2014). These plots were first introduced by Brinley (1965) who used a 
scatter plot in an innovative way to present group mean data from different cognitive 
experiments. Brinley measured cognitive performance speed of groups of young and elderly 
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participants on several different tasks. Mean performance values from each group were 
plotted on a scatterplot to enable comparison of results for the different cognitive tasks for 
each age group. Brinley plots have since been used to display systematic effects of various 
categorical variables on mean performance in a range of psychological experiments 
(Blampied, 2014); for a recent example see Dye, Green, and Bavelier (2009). 
Modified Brinley plots use data from individuals rather than group means (Blampied, 
2007, 2014; Jacobson, Follete, & Revenstorf, 1984; Jacobson & Truax, 1991; Sobell, Sobell, 
& Gavin, 1995; Stunkard & Penick, 1979). Each data point represents an individual’s 
measurement made at time 1 (T1), plotted on the X axis against a measurement on the same 
variable, taken at a later time (Tx), which is plotted on the Y axis. If there is no change of 
scores from T1 to Tx, and the axis have the same origin and scale, then all data points will lie 
along the 45º diagonal line; however, if the intervention has had a systematic effect on the 
participants, then this effect will be evident by movement of the plotted points either above or 
below the diagonal line, depending on whether it is an improvement or deterioration 
(Blampied, 2014).   
Modified Brinley plots are particularly suitable for the analysis of outcome research 
of psychological therapies, and have been said to be especially useful for single-case research 
as they show the effect of an intervention on a group, while also preserving each individual’s 
identity in the display (Blampied, 2007). Interpretation can be assisted by adding lines of 
clinical cut-off for the measure, both at T1 and Tx, (Jacobson, et al., 1984; Jacobson & Truax, 
1991), and means,  confidence intervals, and other measures of variance, and effect sizes can 
also be included (Blampied, 2014). 
Data for the current study are presented as individual participant’s scores on a 
measure at a particular time point, plotted against their score on the same measure at another 
specified time point. As noted above, a treatment effect is evident when scores deviate from 
62 
 
the 45º diagonal line. For both the PIRS and DASS, data points that fall below the line show 
a decrease in score and therefore an improvement on this variable, while data points that fall 
above the line show an increase in score and therefore deterioration. Arrows displayed on the 
graphs show this directional change that is indicative of improvement. The crosses on each 
graph represent the group mean for each time point, and in some graphs Cohen’s d(within) 
effect sizes are also displayed.  

























































Figure 7.Clinical interpretation of a Modified Brinley plot where improvement is shown 
by a reduction in score (see the arrowhead on the vertical pre cut-off line). The solid 
diagonal line is the line of no effect, and the dashed diagonal lines show the Reliable 
Change boundaries where Reliable Change = +/- 1.96xSEM (after Truax & Jacobson, 
1991) 
 
3.4.1 Changes in PIRS over Time in Multiple Baseline Format. Figure 8 shows the 
effect of the micronutrient intervention on the primary measure of insomnia severity, the 
Pittsburgh Insomnia Rating Scale (PIRS). Consistent with the multiple baseline design, 
participants received baseline lengths of one week, two weeks or three weeks, and their initial 
screening score was treated as an additional baseline score.  Each participant’s weekly PIRS 
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score is plotted against their initial screening score, thus showing change over time relative to 
initial screening. As noted above, in the absence of any change over time, all data points 
would lie on or closely about the diagonal line. Increases in PIRS scores at any time point are 
shown by points above the line, and decreases by points below the line. The bold dashed line 
in the figure demarcates baseline weeks from subsequent treatment weeks. The data points 
show little dispersion on the X-axis because (a) participants were selected to be above a 
clinical cut-off of 98 on the PIRS, and (b) because each individual’s point in the plot is 
referenced to their initial screening score, and is constant across graph panels. Treatment 
Week 4 (the mid-point of the treatment phase) and the last week of treatment (Week 8) are 
then shown in plots to the right of the baseline plots. These weeks were chosen to (a) allow 
for any delayed treatment effect to emerge (Week 4) and (b) to show the effect of treatment 
after full exposure to the micronutrients (Week 8). 
The top line of plots present data for the group with one week baseline. The initial 
plot, presenting initial PIRS score versus Baseline 1, shows that two participants had a small 
decrease in insomnia rating during baseline, while the other two showed a slight increase. 
The middle line of plots present data for the group with two weeks baseline. The initial two 
plots presenting initial PIRS versus Baseline 1 and Baseline 2, show a slight deterioration in 
the first week of baseline, and a move back towards the line of no change during the second 
week of baseline. The third line of plots presents data for the group with three weeks 
baseline. The first three plots compare initial PIRS with Baseline 1, Baseline 2 and Baseline 3 
respectively, and show that three Participants show a slight improvement during baseline 
weeks, while one Participant shows an increase in insomnia severity. Overall, to a large 
extent these baselines were stable across the weeks, although there was a trend for the group 
with a three week baseline to show slight improvement during this phase.  
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The mid-point plots compare each participant's initial PIRS score with their score 
after four weeks of intervention. For the first group, the plot shows that by the mid-point of 
intervention, all four participants have shown a decrease in insomnia severity, in the second 
group both participants have also shown an improvement, and this is replicated in the third 
group where all four participants have also shown a decrease in insomnia severity. The 
reductions in PIRS scores shown in this week are consistently larger than any reductions 
observed in any baseline week. The general trend across plots is that a treatment effect is able 
to be detected after four weeks of micronutrient intervention.  
The Treatment Week 8 plots compare each participant’s initial PIRS score with their 
score at the end of the treatment phase. For the first group we can see that three out of four 
participants have shown further improvement, while one participant is showing some 
deterioration towards baseline. In the second group one participant has sustained their 
improvement at mid-point, and the other’s data point is missing for this time point. All 
participants in the third group showed further improvement relative to Week 4. Overall, the 
majority of participants were showing a treatment effect by mid-point and this treatment 
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Figure 8. Modified Brinley plots showing the effect of a micronutrient intervention on 
insomnia severity in a multiple baseline format as measured by the PIRS. The bold 
dashed line separates baseline phases (on the left) from treatment phases on the right. 
Data from each week of baseline are shown for all participants, then from the mid-point 
of treatment (Week 4) and then from the last week of treatment (Week 8). The diagonal 
line is the line of no change over time; improvement is indicated by points below the 
line.  [NB: Ns for the 1-week and 3-week baseline group = 4 throughout. One 
participant ceased recording data during the treatment phase for the 2-week group, so 





In summary, Figure 8 shows a trend for relatively stable baselines across weeks, with 
a slight tendency for the third group to show slight improvement in baseline phase. By the 
mid-point of intervention all participants are showing a treatment effect, and by the end of 
intervention the majority of participants show a larger effect. 
3.4.2 Plots of Weekly Changes in PIRS over Treatment Phase. Figure 8 examined 
changes in PIRS scores for Treatment Weeks 4 and 8 relative to initial screening score, and 
examined the stability of scores across baselines of different lengths and the replication of the 
treatment effects across the different baseline-length groups. Figure 9 shows the effect of the 
micronutrient intervention on insomnia as rated by the PIRS, referencing each individual’s 
weekly score against their mean score in baseline, again using modified Brinley plots. Given 
the evidence from Figure 8 that baseline scores were relatively stable, individual’s mean 
baseline scores can be reported with confidence that they accurately, but conservatively, 
represent baseline performance (for a fuller discussion of the issues arising in selecting 
baseline reference values, see Blampied, 2014).  Mean baseline scores were computed 
participant by participant, by combining the initial screening score with all subsequent 
baseline points. The number of scores averaged thus depended on which baseline length 
condition the participant was assigned to (1, 2 or 3 weeks). In Figure 9 the bold cross on each 
graph panel shows the overall mean for the week plotted against the overall mean baseline 
score, and these means were used to compute Cohen’s d(within)  Effect Size for each week. 
Cohen’s d was computed using the formula 
𝑀𝑒𝑎𝑛(𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒)−𝑀𝑒𝑎𝑛(𝑤𝑒𝑒𝑘)
𝑆𝐷𝑎𝑣𝑒𝑟𝑎𝑔𝑒
 taken from Cumming 
(2012), such that improvement in insomnia symptoms is related to a positive ES.  
The initial plot presenting mean of Baseline versus Intervention Week 1 shows that 
approximately one third of participants showed no change, one third showed a small 
improvement, and the final third are already showing a moderate improvement in insomnia 
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severity. Cohen’s d for this plot (1.04) indicates that a large treatment effect is already 
evident.  Over the next three plots all participants show a decrease in scores and appear to 
split into two clusters, one cluster showing small to moderate improvement, and the other 
showing moderate to large improvement. As the weeks progress, the effect size continues to 
increase in magnitude (e.g. d= 2.92 at Week 4). These trends can be seen across the 
remaining four plots and by Week 8 the mean of scores has dropped from 109.8 at baseline to 
40.33, with an effect size of d= 3.42 which is more than three times the effect size at Week 1. 
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Figure 9. Modified Brinley plots showing the effect of micronutrient intervention on 
insomnia severity week by week, as measured by the PIRS. The cross shows the 
composite mean for the week plotted against the composite baseline mean. Cohen’s d 
Effect Size is also shown week by week. [NB: Weeks 1 – 3, n = 10, Weeks 4 – 8 n = 9. A 




3.4.3 Summary of Findings from Primary Outcome Measures. Primary outcome 
measures included data from the daily sleep diaries and the PIRS. Individual changes across 
baseline and intervention phases, as reported in daily sleep diaries, were presented using time 
series graphs following the conventions of the multiple-baseline design. These graphs showed 
that seven out of twelve participants (58.3%) showed a moderate or large treatment effect, on 
at least four of the five variables measured. Three of the twelve participants (25%) showed a 
moderate or large treatment effect on some of the variables, and only two participants (16%) 
showed no treatment effect. Overall, ten out of twelve participants, or 83%, showed a 
treatment response to the intervention as measured by the daily sleep diaries. 
 Modified Brinley plots were used in multiple-baseline format to analyse individual 
changes in the PIRS measure. Figure 8, which compares each participant’s initial score, with 
final baseline, Treatment Week 4 and Treatment Week 8, shows a trend for relatively stable 
baselines across weeks, with a treatment effect evident for all participants at Week 4, and a 
larger effect for most participants by Week 8. This trend is replicated in Figure 9, which 
shows a treatment effect at Week 1 of intervention (d= 1.04), that increases in magnitude 
with each passing week. By the end of treatment (Week 8), the group mean of scores has 
dropped from 109.8 at Baseline, to 40.33, with an effect size of d= 3.42, a very large effect. 
3.4.4 Changes over Time in DASS; Depression, Anxiety, and Stress. The DASS 
subscales of Depression, Anxiety, and Stress were considered secondary measures in this 
study, and were included to assess any general changes in psychological wellbeing 
concurrent with changes in the primary sleep and insomnia measures. Figures 10, 11 and 12 
show the effect of the micronutrient intervention on depression, anxiety and stress, as 
measured by the DASS, referencing each individual’s weekly score against their mean score 
in baseline, again using modified Brinley plots. The bold cross on each graph panel shows the 
overall mean for the week, plotted against the overall mean baseline score. As with the PIRS 
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data, mean baseline scores were computed participant by participant, by combining the initial 
screening score with all subsequent baseline points. Also as for the PIRS, reductions in DASS 
scores are indicative of improvement. 
Depression:  In Figure 10 the initial plot presenting means of Baseline versus 
Intervention Week 1 shows that the majority of participants started to report small 
improvements in depression levels in the first week, relative to their baseline levels. The next 
three plots show that three participants are showing a moderate to large improvement, three 
are still only showing very slight improvement, and two have actually gotten worse. By the 
mid-point (Week 4), the treatment effect size is moderate (d = 0.64). Over the remaining four 
plots, all participants show improvement and by Week 8 the mean of the Depression scores 
has dropped from 10.46 at Baseline to 3.56, with a large effect size of d = 1.46. 
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Figure 10: Modified Brinley plots showing weekly effect of micronutrient intervention on 
mood as measured by the Depression Subscale of the DASS. Cross marks the mean for 
each week relative to the overall Baseline mean. 
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Anxiety:  In Figure 11 the initial plot presenting means of Baseline versus 
Intervention Week 1 levels of Anxiety shows that already the majority of participants 
reported an improvement in anxiety in Week 1 relative to Baseline, and already a large 
treatment effect is evident (d = 0.89). Over the next three plots all except one participant 
continued to improve; by the end of treatment (Week 8) all participants showed further 
improvement, the group mean dropped from 6.58 at Baseline, to 1.33, and the effect size 
increased in magnitude (d= 1.68 at Week 8).  
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Figure 11. Modified Brinley plots showing weekly effect of micronutrient intervention on 
anxiety as measured by the Anxiety Subscale of the DASS. Cross marks the mean for each 





Stress: In Figure 12 the initial plot presenting means of Baseline versus Intervention 
Week 1 shows that a majority of participants showed small or moderate improvement, and 
one participant shows particularly large improvement in reported stress levels by the end of 
the first week of treatment. Over the course of the next three plots all except one participant 
continued to improve and the effect size continued to increase. By the mid-point of therapy 
(Week 4) d= 2.16, and by the end of eight weeks of intervention all participants showed a 
moderate to large improvement, with the group mean decreasing  from 17.43 at Baseline, to 
6.33 at Week 8. The effect size continued to increase and by the end of intervention d= 2.85, 
a large effect. 
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Figure 12. Modified Brinley plots showing the weekly effect of micronutrient intervention 
on stress as measure by the Stress Subscale of the DASS. Cross marks the mean for each 




3.4.5 Summary of the Effect of the Intervention on Insomnia (PIRS) and 
Depression, Anxiety, and Stress (DASS) at Baseline, 8 Weeks, and Follow-up. Figure 13 
provides a summary of the effect of the micronutrient intervention on insomnia severity, 
depression, anxiety and stress as measured by the PIRS and the DASS. Figure 13 plots initial 
scores for each measure against final baseline (i.e., Baseline week 1, or 2, or 3, depending on 
the baseline assigned), treatment Week 8, and follow up scores for each participant. The far 
right hand plot compares treatment Week 8 scores with scores at 3 months follow up to 
examine stability of treatment gains over time (after Stunkard & Pennick, 1979), and as 8 of 
the 9 participants who completed follow-up measures had ceased to take the micronutrient 
this becomes a natural reversal design, in so far as one compares baseline, treatment, and 
follow-up phases.  
Further features are employed in Figure 13 to aid in summarising the findings of the 
study. As noted previously, in the absence of any change over time, all data points would lie 
on the diagonal line. Increases in scores at any time point are shown by points above the 
diagonal line, and decreases by points below this line. Bold horizontal and vertical lines 
indicate the clinical cut-off for the DASS (i.e.,  Depression = 13, Anxiety = 10, and Stress – 
18; Lovibond & Lovibond, 1995) , and the screening cut-off for the PIRS (i.e., 98). Reliable 
change boundaries are shown using dotted lines and the arrowheads show the direction of 
therapeutic change. Reliable Change was calculated for each measure using the procedures of 
Jacobson and Truax (1991). Data points lying below -1.96xSE (SE = Standard Error of 
Measurement) can be considered as showing Reliable positive change (RC+), those lying 
above +1.96xSE as showing reliable deterioration (RC-) and those between the boundaries as 




PIRS: The intial plots compares intital scores with scores at the last baseline measure. 
Participants are clustered very closely to around the diagonal line with some scores slightly 
above and some slightly below, indicating that scores across baseline were relatively stable. 
The second plot, comparing initial scores with treatment Week 8 shows a dramatic movement 
of participants down and away from the diagonal line (in the direction of therapeutic change) 
showing a large treament effect (d= 4.08). All participants are now below the initial cut-off 
score for entering the study, and all particpants sit in the RC+ zoneshowing that this 
treatment effect is unlikely (p< .05) to be due to measurement error. No participant showed 
either deterioration (RC-) or was indeterminate (RCo). The third plot compares intital scores 
with the 3 month follow up, and even though all bar one participant had discontinued use of 
micronutrients at this stage, the participants are still maintaining some improvement, 
although not as dramatic as Week 8. The final plot which compares treatment Week 8 to 3 
month follow up shows that almost all participants have shown no change or have 
deteriorated in the months between the end of treatment and follow-up. This was to be 
expected due to the fact that only one participant conintued using the micronutrient 
intervention after Week 8 (the participant represented by filled dot).  
 
DASS: The initial plots comparing scores at initial screening with scores at end of 
baseline shows that mostly participants show little change across these measures. In the 
Depression scale, two show improvement and one shows deterioration, and in the Anxiety 
scale one shows some improvement while the rest are clustered very closely about the line of 
no change. In the Stress scale one participant shows improvement and one shows 
deterioration. Overall most show little or no change across baseline and are relatively stable 
in baseline. The second column of plots comparing initital score with treatment Week 8 show 
dramatic movement of the points down and away from the diagonal line in the direction of 
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therapeutic change. The majority of participants show a reduction in depression, anxiety and 
stress scores across the intervention phase, with large effect sizes of d= 1.37, d= 1.48 and d= 
2.52 respectively. The percentage showing Reliable Change is also large for both depression 
and stress (67% and 78%), while it is moderate for anxiety (56%). The third row of plots 
comparing initial score with 3 month follow up shows a trend of deterioration back towards 
baseline levels, with some participants worse than at intial screening. Notably, the participant 
who continued with the micronutrient intervention (the filled dot in Figure 13) is one, but not 
the only one of those still showing a treatment effect. The final row of plots compares scores 
at treatment Week 8 with those at follow up, creating a natural reversal design. Across 


































































































































































Figure 13: A summary Modified Brinley plot graph summarising PIRS and DASS data 
over baseline, treatment and follow-up. The filled dot marks the participant who 
continued to take micronutrients through follow-up.  Reliable change boundaries are 
shown using dotted lines, and RC+ shows the percentage of participants showing 





4.1 Summary of Findings 
This study investigated an innovative approach, using a multi-ingredient 
micronutrient intervention for the treatment of insomnia in adults. The results showed that 
treatment with micronutrients resulted in clinically significant decreases in severity of 
insomnia symptoms, and reduced stress, anxiety and depression levels, amongst a sample of 
adults who were suffering from chronic insomnia. This study is the first to use a multi-
ingredient micronutrient to treat insomnia in adults. The findings add a new element to the 
current literature that examines micronutrient interventions for mental health concerns, and 
the positive result is consistent with previous studies which have found that micronutrients 
can significantly improve mood, and reduce levels of anxiety and stress. The current study 
found there were significant improvements with the introduction of micronutrient 
intervention, for all dependent variables, as demonstrated by time series analysis and 
modified Brinley plots. There is considerable agreement that in clinical outcome research, 
information on individual change is of key importance (Blampied, 2014; Jacobson et al., 
1984; Sobell et al., 1995; Stunkard & Penick, 1979), and modified Brinley plots are 
particularly useful in this respect, as they show the effect of an intervention on a group, while 
also preserving each individual’s identity in the display (Blampied, 2007). 
Fourteen individuals participated in the trial, one participant withdrew following the 
first three days of the intervention phase and another following week four of the intervention 
phase. The participants recruited reflected a group of adults who were experiencing moderate 
to severe levels of insomnia, measured using the Pittsburgh Insomnia Rating Scale.  
The hypotheses were generally supported by the results of the study. The primary hypothesis 
predicted that micronutrient intervention would be associated with reduced severity of 
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insomnia symptoms. This hypothesis was supported such that all participants showed a 
decrease in insomnia severity during intervention phase, and by the end of treatment (Week 
8) the group mean PIRS score had dropped from 109.8 at baseline, to 40.33, with a large 
effect size of d = 3.42.    
Reliable change was also calculated for each the PIRS and DASS measures (Jacobson 
& Truax, 1991), and the percentage of participants showing reliable positive change (%RC+) 
was used as another measure of effect size. By Week 8 of treatment, all participants, or 
100%, were in the reliable positive change zone for the PIRS, indicating that this treatment 
effect is unlikely (p< .05) to be due to measurement error. Reporting the percentage showing 
positive reliable change is complimentary to Cohen’s d as it says how many participants 
changed positively to a degree plausibly larger than measurement error, while being silent 
about the size of the change. On the other hand, d measures the size of the mean change, 
scaled by the standard deviation, and using both gives more information than either effect 
size alone.  
The second hypothesis, that improvement in insomnia symptoms would be endorsed 
by daily sleep diaries, was also supported. The diaries showed that during the intervention 
phase, five out of twelve (42%) participants showed a moderate or large treatment effect on 
measures of sleep onset latency, six out of twelve (50%) showed a moderate or large 
treatment effect on frequency of night waking, and nine out of twelve (75%) participants 
showed a moderate or large treatment effect on total sleep duration. Daily sleep diary data 
also confirmed that nine out of 12 (75%) participants also showed a moderate or large 
treatment effect on measures of sleep efficiency, and six out of twelve (50%) showed a 
moderate or large treatment effect on feelings of restedness upon waking. 
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Although there was a tendency for a small improvement on some measures during 
baseline, the majority of baseline measures showed predominantly stable baseline phases, 
followed by much steeper improvement during the intervention phase. This improvement was 
seen across multiple dependent measures and by the majority of participants, demonstrating a 
compelling treatment effect, above that of trends towards regression to the mean.  
The third hypothesis, that micronutrient intervention would be associated with 
reduction in levels of stress, anxiety and depression, was also supported. Out of the ten 
participants who completed the DASS measures, all experienced a reduction in depression 
rating during treatment. By the end of treatment Week 8, the group mean depression score 
had dropped from 10.46 at baseline to 3.56, with a large effect size of d = 1.46, and the 
percentage showing Reliable Change was also large at 67%.   
All participants also showed a reduction in anxiety, and the group baseline mean of 
6.58 dropped to 1.33 by end of treatment, with d = 0.89, a large treatment effect, and a 
moderate percentage showing Reliable Change of 56%.    
Further, all participants showed a moderate to large improvement in stress levels, with 
the group baseline mean of 17.43 reducing to 6.33 by Week 8. A large treatment effect was 
also detected for this variable and by treatment Week 8, d= 2.85, and a large percentage 
(78%) showed reliable positive change. 
Some quotes from participants illustrate the experience of the intervention in a 
qualitative way. At the end of the intervention phase, one participant stated “I have noticed a 
huge difference, when I wake up I can go back to sleep rather than staying awake, and I wake 
up feeling great”, another participant stated “I have never slept this well”. Another participant 
commented “I don’t think I have ever slept better, my main issue has always been getting to 
sleep, it took a long time, sometimes hours, now (end of intervention) it takes a maximum of 
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30 minutes, and normally less”, the same participant also said “I have better quality sleep, 
I’m less worried about sleep and I wake up with better energy levels”. Another participant 
stated “The nutrients started working after about two weeks and made a great difference, I’m 
not waking up nearly as much, and lots of nights I’m not waking up at all”. 
Intervention with the micronutrient supplement was associated with mild side effects 
in four out of fourteen participants. One participant experienced a mild stomach upset for the 
first few days of taking the capsules which then passed. One participant reported a very dry 
mouth at the beginning of their fourth week taking the capsules which had passed by the end 
of the week. Another participant reported experiencing an increase in intensity of sensations 
such as sights and sounds during the seventh week of intervention, although they were unsure 
if this was related to the capsules. A fourth participant reported headache, reflux, mild nausea 
and dizziness after starting the intervention. This participant decided to withdraw from the 
study during the first week of taking the capsules due to the side effects experienced. 
Of the twelve participants who completed the entire intervention phase, all (100%) 
were compliant in terms of adherence to the treatment protocol. This involved taking the 
recommended micronutrient dose (six capsules) daily, without missing a significant number 
of doses, which was defined as a compliance rate of greater than 80%, or no more than 67 
missed capsules across the intervention phase. Of the twelve compliant participants, eight 
reported perfect compliance, two participants reported a total of 3 missed capsules, one 
reported a total of 27 missed capsules, and one participant reported a total of 30 missed 
capsules. 
The final hypothesis, that improvements would be maintained or increased over the 
follow up period for those who chose to stay on the micronutrient intervention was difficult 
to examine due to the fact that despite significant improvement during intervention phase for 
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many participants, only one participant continued to take the capsules after treatment Week 8. 
Reasons stated for not continuing included cost, access, life stress. The two participants, who 
did not experience a treatment effect during the study, stated that they had discontinued the 
micronutrients as they had not found them beneficial. 
 The follow-up period, therefore, became a natural reversal design. The one 
participant who remained on the intervention showed little or no further improvement 
between end of intervention phase and 3 month follow-up, while the majority of other 
participants showed some deterioration back towards baseline. 
At the three month follow up, a participant who had stopped taking the nutrients 
reported “I'm a little more restless during the night and it is slightly harder to get to sleep.” 
another said “my sleep wasn’t as good two weeks after stopping the supplement”. Another 
participant commented “I am much more anxious than I was during the period that I was 
taking the micronutrients, I am going to go back to taking them as I believe they greatly 
improved my quality of life." 
The novel findings of the current study build on previous research demonstrating the 
positive effect of micronutrient intervention with broad spectrum micronutrients in those with 
mental health problems. They support and replicate findings from a number of other studies 
which have demonstrated the therapeutic effect of micronutrients (specifically EMPowerplus)  
on mental health problems such as bipolar disorder, OCD, ADHD, stress and anxiety (Kaplan 
et al., 2007; Kaplan et al., 2002; Kaplan et al., 2004; Kaplan & Leung, 2011; Kaplan et al., 
2001; Lewis Mehl-Madrona, Brenda Leung, Carla Kennedy, Sarah Paul, & Bonnie J. Kaplan, 
2010; Popper, 2001; Rucklidge, 2009; Rucklidge et al., 2012; Rucklidge et al., 2014; 
Rucklidge et al., 2010; Rucklidge & Harrison, 2010; Rucklidge, Harrison, & Johnstone, 
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2011; Rucklidge, Johnstone, et al., 2011; Rucklidge & Kaplan, 2013; Rucklidge, Taylor, et 
al., 2011).  
This research has demonstrated a positive treatment response when using 
micronutrients for the treatment of insomnia, and showed that this intervention has a minimal 
side effect profile (i.e., side effects were mild and transitory) when compared with 
pharmacological treatments, and continues to exhibit a treatment effect over an extended 
period. Hypnotic medications, used to treat insomnia, frequently cause daytime impairment 
and sedation due to their half-life, and are only safe for short term use (Sateia & Nowell, 
2004). Their usefulness is limited to insomnia of short duration (less than four weeks) as after 
this time their therapeutic effect wears off and with continued use, addiction can develop 
(Touitou, 2007). Furthermore, withdrawal effects of hypnotic medications have been well 
documented and can last as long as five weeks following discontinuation. Given that 
withdrawal appears to be related the dose taken and the length of time that the hypnotic is 
taken for, long term treatment with hypnotics is not appropriate (Rothenberg, 1997). The 
minimal side effect profile and long term effectiveness of the micronutrient intervention are 
therefore particularly notable as they provide an effective and non-addictive alternative to the 
pharmacological treatments currently available. 
Other research that has investigated the impact of multi-ingredient micronutrient 
formulas (not EMP+) on mental health conditions has also found a positive treatment 
response. It is challenging to compare these studies to each other and to those which use 
EMP+, due to the varying formulas and doses used. However, the overall findings from the 
current study suggest a strong potential for the use of multi-ingredient micronutrient 
formulas, including EMP+, in the treatment of sleep difficulties, anxiety, stress and depressed 
mood in adults.  
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The exact mechanism through which micronutrient formulas produce a treatment 
effect is not yet known. Kaplan and colleagues (2007) have discussed four possible 
conceptual frameworks that could explain how micronutrients might act within the brain to 
treat the symptoms of mental health disorders. These models are discussed by the authors as 
being compatible rather mutually exclusive or exhaustive, and may explain co-existing 
pathways through which micronutrients exhibit their therapeutic influence on mental health.  
The first model suggests that unstable mood may be the manifestation of inborn errors 
of metabolism, which can affect brain function through their influence on enzyme and 
coenzyme reactions (Ames, 2004). These inborn errors can diminish the binding affinity for a 
coenzyme by a known enzyme, which then leads to a lower rate of metabolic activity. Ames 
and colleagues (2002), investigated human genetic diseases that are associated with this type 
of inborn error and found that in most cases, symptoms could be corrected by treatment with 
additional cofactors (micronutrients). It is therefore plausible, that, in some cases of mental 
illness, inborn errors of metabolism may slow metabolic activity involving neurotransmitters, 
contributing to the development of psychiatric symptoms. Treatment with additional 
micronutrients may serve to facilitate this metabolic activity, thereby enhancing 
neurotransmitter activity within the brain and leading to the resolution of mental health 
symptoms (Kaplan & Leung, 2011). 
The second conceptual framework explains how psychiatric symptoms could occur as 
a product of deficient methylation reactions (Kaplan et al., 2007). Methylation, or adding a 
methyl group to a molecule, is integral to many brain processes, especially those involved in 
the synthesis of neurotransmitters. Given that micronutrients are a vital ingredient in 
methylation, the authors suggest that  micronutrient treatment may enhance the methylation 




 Another theory is that psychiatric symptoms are the result of alternations of gene 
expression, caused by nutrient deficiency. It has been well established that the level of 
available nutrients can alter the expression of genes, and in this case they may be responsible 
for the expression of genes involved in mental health disorders, many of which have been 
found to have a genetic component (Kaplan et al., 2007; Kaplan & Leung, 2011). Ames’s 
(2010) triage hypothesis proposes that nature ensures our survival by altering metabolism 
within the body when the availability of micronutrients becomes limited. Nutrients are 
redirected towards those processes most essential for our immediate survival, albeit at the 
expense of the body’s long term health, and this can lead to long term degenerative disorders. 
Perhaps mental health conditions reflect long term suboptimal levels of micronutrients 
necessary for brain function, resulting in malfunctioning brain processes and deterioration in 
mental health  (Kaplan et al., 2007). 
Impairment in mitochondrial function has also been implicated as an underlying 
contributor to a variety of neurological and psychiatric disorders (Kaplan & Leung, 2011). 
Elevated levels of oxidative stress can contribute to neuronal damage, and it is possible that 
psychiatric symptoms may be the manifestation of deficiencies in micronutrients that are 
needed to remedy this oxidative stress. 
While the exact causes of an individual's insomnia are thought to vary, the majority of 
research identifies heightened arousal, anxiety, worry and rumination, as being leading 
factors in the cause and maintenance of sleep disruption (Bootzin & Epstein, 2011). Events 
that are emotionally stressful have been found to impact sleep quality and wellbeing, and are 
believed to do so through triggering cortical and emotional arousal (Wuyts et al., 2012). 
Several psychological and physiological aspects can contribute to the onset and maintenance 
of insomnia. Anxious-ruminative personality traits, life stressors, homeostasis weakening 
mechanisms, and biologic or genetic central nervous system hyper-arousal have all been 
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identified as factors that can be involved (Basta, 2007). It is therefore plausible that through 
the correction of inborn errors of metabolism, enhancement of the synthesis and activity of 
neurotransmitters, and the continuous availability of an abundance of micronutrients, issues 
of biologic or central nervous system hyper-arousal may be amended, and the brains ability to 
process emotional stress may be enhanced. 
 These theories and models propose pathways through which micronutrient 
interventions may exhibit their therapeutic effect on mental health symptoms. As mentioned 
above, these mechanisms are likely to be interrelated and there is much overlap that occurs 
between them. Overall, the theories indicate that some individuals may require higher levels 
of available micronutrients than others, and that perhaps some require levels higher than are 
obtainable through diet. 
Depletion of nutrients in the food supply should also be considered. Research shows 
that the levels of minerals and trace elements in fruits and vegetables have been diminishing 
over the past 50 years (Ekholm et al., 2007; Mayer, 1997), and the modern Western diet is 
typically dominated by refined, processed carbohydrates, with limited amounts of fresh 
produce (Cordain et al., 2005). Thus, it is likely that many Westerners are consuming 
suboptimal levels of micronutrients, and are therefore vulnerable to the problems described in 
the models above. It may be that certain individuals are particularly vulnerable to these 
nutritional depletions in food due to different biochemical needs (Rucklidge, Taylor, et al., 
2011). The literature is demonstrating that supplementation with multi-ingredient 
micronutrient formulas can remedy these deficiencies and may be a promising and innovative 







One limitation of this study was the open label nature of the trial and the lack of 
placebo control. Both the participant and researcher were aware that they were in active 
intervention phase and this can make both parties susceptible to expectancy effects. While we 
cannot rule out a placebo effect, there are many reasons that it is unlikely to have explained 
the therapeutic effects; for example, most participants showed some delay in treatment 
response after beginning the nutrient intervention, and even those who showed an initial 
improvement mostly showed only a small effect which increased in size the longer the 
individual was taking the micronutrients. A placebo effect would be expected to occur 
immediately, rather than gradually growing in magnitude over the weeks. Participants were 
also informed several times prior to beginning the study that this was an experimental 
treatment and that the researcher did not know if it would be effective. Many of the 
participants had trialled other treatments in the past, including natural over-the-counter 
remedies, none of which they found effective in the long term, which makes it unlikely that it 
would only be with this intervention that they experienced a placebo effect. So while in this 
case placebo effects cannot be ruled out, there are a number of reasons why they are unlikely 
to be responsible for the therapeutic effect found.  
This study is a pilot trial, and the promising results bring to attention the need for 
future placebo-controlled research into the effect of micronutrient intervention for insomnia. 
Initially, direct replication with a larger sample would be useful to establish the reliability, 
and replicability of the research findings. Randomised controlled trials, reversal trials and 
effectiveness trials (where the intervention is tested in a clinical environment) could all be 
used to systematically establish the replicability of the effect found in the study. Generality 
could be explored through systematic replication, where various attributes of the participants 
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(age, gender), or of the treatment (dosage, length of intervention) are systematically varied 
(Blampied, 2013), and the effect on the treatment outcome is examined. 
Spontaneous remission of symptoms must be considered when interpreting the results 
of the study. However, given that a majority of participants experienced a therapeutic effect 
despite experiencing chronic insomnia, it is unlikely that spontaneous remission is 
responsible for the positive effect observed. Also, baseline data showed the baseline phase to 
be relatively stable, with a steep improvement during the intervention phase, making 
spontaneous remission of symptoms an unlikely to explanation.  
 Participation in research trials involves exposure to regular therapeutic input, 
including contact with the therapist, assessment of symptoms, assistance provided to ensure 
compliance, and empathic responses. It must be considered that contact with the researcher 
may have contributed to the effects seen in this study. However, it is unlikely that this 
therapist effect could have accounted for the compelling treatment effect seen in the study, 
contact with researcher was minimal and only occurred at three points during the study (the 
beginning, middle and end). All measures were completed online or filled out at home in 
sleep diary format, limiting the amount of contact with the researcher. Furthermore, 
appointments were focused purely on maintaining compliance, checking for side effects, and 




With any novel treatment approach, feasibility is an important consideration. An 
important factor, that became an issue of feasibility during this study, was participant 
compliance with completing measures. Some participants struggled with remembering to 
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complete their daily sleep diaries and weekly online measures, and in future, more effective 
strategies for reminding participants to complete measures would be essential. During the 
current study email prompts were used; however, the success of this strategy relied on 
participants consistently checking their emails, and so perhaps in future daily text reminders 
would be more effective. 
 Side effects caused by the intervention must also be noted as impacting the 
feasibility of the study. Four participants (28%) experienced side-effects that may have been 
associated with the intervention, and while only one participant experienced side effects that 
were not transient, the effects caused the participant to cease participation in the study. 
One of the biggest feasibility considerations that arose during this study was the 
financial commitment of continuing the micronutrient capsules at the end of the intervention 
phase. Although the majority of participants reported improvements during the intervention 
phase, all except one stopped taking the nutrients at the completion of trial. Many named cost 
and availability as the main reasons preventing them continuing with the intervention. Future 
research should investigate if therapeutic gains achieved with the relatively expensive 
micronutrient formula used here might be maintained if participants switched to less 
expensive over-the-counter vitamin and mineral preparations, or perhaps made more 
extensive changes in their diet to enhance the nutritional value of their food. 
Challenges for the researchers included arranging suitable appointment times with 
participants that were not during work hours, and that accommodated those who had young 
children. Another challenge was ensuring that participants filled out measures within the 
required time frame. Communication via phone, text and email was useful in this respect, 
however, in future it would be recommended that text be used more predominantly as email 
was not always found to be a reliable or efficient way to contact participants.  
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4.4 Further Research 
As many people seek alternative treatments for mental health difficulties because of 
the limited availability and financial constraints of psychotherapeutic interventions, and the 
side effects and long term impact of medications, further options for treating these difficulties 
deserve exploration (Rucklidge & Kaplan, 2013). 
As with pharmaceuticals, the current micronutrient research has not yet documented 
their long-term safety over years and decades (Rucklidge & Kaplan, 2013), and further 
research should establish the longer term safety and efficacy of multi-ingredient formulas. 
Trialling longer intervention phases using groups at varying doses would be useful to 
investigate under which conditions the therapeutic effect plateaus, and to determine the dose-
response relationship. It is certainly plausible that the optimum therapeutic dose varies 
between individuals, and perhaps some would respond better at a higher dose than used in the 
current study.  
Further research needs to replicate the current findings to establish the reliability of 
the therapeutic effect, and would benefit from the use of placebo-controlled trials to account 
for the possibility of placebo or expectancy effects. It would also be interesting to conduct a 
trial directly comparing micronutrient intervention with current psychotherapeutic and 
pharmacologic interventions for insomnia.  
Authors Rucklidge and Kaplan (2013) anticipate that a healthy gastrointestinal system 
will be considered essential in the future for maximising the treatment response to nutrient 
interventions. The health of the gut has been identified as impacting significantly on the 
absorption of nutrients, and it may be that an individual’s gut flora influences their ability to 
respond to the treatment. Administering participants with probiotics before and during 
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micronutrient intervention may provide a way to improve response rate and magnitude, and 
would be a useful avenue to explore. 
 
4.5 Conclusion 
 In conclusion, the results of the current study provide evidence that multi-ingredient 
micronutrient formulas are a promising treatment option for adults suffering from symptoms 
of insomnia. The findings give additional support to research indicating that micronutrient 
treatments are associated with improvements in psychiatric symptoms and overall 
functioning. Further placebo controlled research trials, that establish replicability, appear 
warranted. It is imperative that safe and effective treatment options are available, and is 
essential that researchers and clinicians are willing to investigate new and promising areas to 
provide clients with the most beneficial treatment options. Future research investigating the 
effect of multi-ingredient micronutrient formulas on mental health symptoms may provide 
further support for the use of micronutrients in this area. As knowledge is gained about the 
mechanisms through which these formulas exert their therapeutic effect, and absorption and 
dosage is further investigated, it may be possible to further optimise the treatment response 
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Appendix A: Participant Information Sheet and Consent Form 
                
 
 
INFORMATION SHEET: 31st October 2012 
 
Title of research project: Investigation into the effect of a nutritional supplement on 
symptoms of insomnia in an adult population; pilot study using multiple baseline design. 
 
Principal Investigator:  Joanna Lothian 
    (Joanna.Lothian@pg.canterbury.ac.nz) 
      
Other investigators: Assoc Prof Julia Rucklidge (Julia.Rucklidge@canterbury.ac.nz), 
Assoc Prof Neville Blampied 
 
What is the purpose of the study? 
This study is interested in investigating the impact of a micronutrient formula on symptoms of 
insomnia, including onset, duration and quality of sleep. The supplement we are studying is 
called Daily Self Defence (Revised version of EMPowerplus), and it contains 48 vitamins, 
minerals and amino acids. In previous research, these micronutrients have been found to 
reduce levels of stress, anxiety and intrusive thoughts in participants, and have anecdotally 
been reported to improve sleep. You have been invited to participate in the study as you 
completed the online eligibility screen and were rated as having insomnia symptoms of a 
moderate or severe quality. You are eligible for this study as you are not currently taking 




It has been proposed that some vitamins and minerals might help people with a variety of 
psychological concerns such as stress, anxiety, poor attention and low mood. There have 
been anecdotal reports of improved sleep from participants of these studies but impact on 
sleep has not been systematically assessed and researched. It is plausible that if the 
micronutrients reduce stress, anxiety and intrusive thoughts, they may also improve 
symptoms of insomnia. When a new idea such as this comes along, it is best to first study it 
in a variety of people (referred to as case series), to determine that there is an effect.  
 
 
What would I have to do? 
Potential participants will first be directed to a website, www.mentalhealthandnutrition.co.nz, 
that will provide them with more information about the study and will ask them some brief 
screening questions, collect demographical information, complete some questionnaires on 
insomnia symptoms, severity, and levels of depression, anxiety and stress, and provide 
contact details. This initial screening process should take approximately half an hour. On 
submission of the information, eligible participants will be contacted and invited to come to 
the university to meet with the researcher, sign consent forms, and receive the nutrients and 
sleep diaries. The first meeting with the researcher will take up to an hour. 
Once it has been established that you are eligible to participate, you will be randomized to 
one of three groups: 1) Baseline length of 1 week, then 8 weeks taking 6 DSD pills per day, 
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2) Baseline length of 2 weeks, then 8 weeks of taking 6 DSD pills per day, 3) Baseline length 
of 3 weeks, then 8 weeks of taking 6 DSD pills per day. 
 
During the baseline period and the 8 week treatment period when taking the capsules, you 
will be asked to complete a daily sleep diary which measures several aspects of your sleep 
pattern, as well as adherence with pill taking. Completing the sleep diary should take 
approximately 5 minutes each morning. You will also be asked to complete two online-
questionnaires, on a weekly basis. These questionnaires will take approximately half an hour 
in total. These will assess your stress, anxiety and depression levels, and the severity of the 
insomnia symptoms you are experiencing. We will follow up with you three months following 
the end of the study regardless of whether you continued to take micronutrients and ask you 
again to complete these questionnaires. 
 
During the 8 week trial when taking the capsules, you will have two appointments with the 
primary investigator, first at the end of 4 weeks of treatment, and again at the completion of 
the final week of treatment with the micronutrients.  At your appointments, you will complete 
the weekly questionnaires for that week, and be able to speak to the investigator about any 
concerns or questions you have. The appointments will take no longer than an hour. 
 
If you must take an antibiotic or antifungal agent orally for a health problem, it may be 
necessary for you to withdraw from the study for the time you complete the course of the 
drug. This is because antibiotics and antifungal drugs can interfere with the absorption of this 
nutrient supplement. 
 
You will be asked to not try any alternative medicines or other forms of therapy until you 
have completed your involvement in this study. In addition, you are strongly encouraged to 
completely avoid alcohol, marijuana, caffeine, nicotine, and street drugs through the study as 
these substances may decrease the potential benefits of the treatment. At your 
appointments, and in your sleep diary, you will be asked to estimate your use of these 
substances. 
 
Members of all cultures will be encouraged to participate in the study. Respect for Maori 
customs and traditions are of the highest priority and if necessary, home visits with a cultural 
advisor can be conducted. The researchers are available to discuss the research with the 
whanau to assist in developing their understanding of sleep disorders and how they can 
impact on Te taha hinengaro (mental wellbeing), whanaungatanga (family relationships), 
taha wairua (spiritual wellbeing) and taha tinana (physical wellbeing). 
 
What are the risks? 
 
Although we have no reason to suspect that this supplement can harm a physically healthy 
individual in any way, we will monitor you throughout the trial by asking you whether you are 
experiencing side effects or other changes to your physical or mental health. 
 
This type of supplement has been used by many people for many years without any 
unpleasant results reported. More recently, investigators in Canada have published a 
research paper outlining the safety of the micronutrients being studied. Data were 
assembled from all the known published and unpublished studies for the complex formula 
with the largest amount of published research in mental health. Biological safety data from 
144 children and adults were available from six sources: there were no occurrences of 
clinically meaningful negative outcomes/effects or abnormal blood tests that could be 
attributed to toxicity.  In our trials conducted here at Canterbury, we have assessed to date 
over 100 participants taking micronutrients for up to 4 months. There were no abnormal 
blood results that concluded that these micronutrients were having an adverse effect on liver 
107 
 
and kidney function. Further, any side effects reported by this sample were temporary and 
mild. 
 
The most common ‘side effects’ are that previously-experienced constipation has been 
relieved and that the patient is sleeping better; i.e., positive side effects rather than adverse 
events. Other side effects that are reported by people taking micronutrients are headaches 
and stomach aches, although they are typically mild and transitory. These difficulties can be 
avoided by taking capsules on a full stomach, and so we suggest you always take your 
capsules with food and plenty of water. We will review side effects weekly and make a 
referral to a medical practitioner if necessary. We are happy to provide you with copies of the 
studies that have been done to date on EMP+. 
 
Micronutrients have the potential to interact with other medicines or drugs so you should 
avoid taking other medicines whilst on this treatment. For this reason, we are only including 
individuals in the study who are not being concurrently treated for their illness using 
prescribed medications. With respect to whether to take other medications, such as over-
the-counter medications to treat colds, flu, stomach upset and sleep problems, because they 
may interact with the micronutrients, you should first discuss with us or your pharmacist 
before use. Pain killers such as Aspirin, Nurofen, Brufen or Voltaren (the NSAIDs or non-
steroidal anti-inflammatory drugs) should be avoided whilst on the micronutrients as they can 
affect the ability of your blood to clot, and hence stop bleeding from a cut, in a similar way to 
some of the ingredients of DSD. So for example, if you needed a pain killer for a headache, 
it would be safer for you to take Paracetamol or Panadol than Nurofen whilst on DSD.  
 
For safety reasons if you are, or become pregnant, you will have to withdraw from the 
study. Pregnancy should be avoided while taking the supplements. Further, we advise that 
during the trial, if relevant, you use appropriate contraception. 
 
Will I benefit if I take part? 
There may or may not be a direct medical benefit to you. Your insomnia symptoms may be 
improved during the study, and your anxiety, stress and depression levels may decrease, 
but there is no guarantee that this research will help you. The information we obtain from this 
study may help us to provide better treatments in the future for patients suffering from 
insomnia. 
Do I have to participate? 
If you decide not to participate in this study, or if you decide part-way through that you want 
to stop, you are certainly free to do so. This decision will not influence your ongoing health 
care in any way. Similarly, the study’s investigators might choose to end your participation in 
the study at any time for any reason. If new information becomes available that might affect 
your willingness to participate in the study, you will be informed as soon as possible.  
 
Will I be paid for participating, or do I have to pay for anything? 
Arrangements will be made with each individual participant to ensure that your transportation 
costs to the university (to meet with the investigator) are covered. The capsules that you will 
take during the study will be provided at no cost.  
 
Will my records be kept private? 
All information about you that is collected in this study will be held in the strictest confidence. 
The only people who will have access to the information are the study investigators. The 
information will be stored in a locked filing cabinet in a locked room that only the 
investigators will have access to. We are very careful in dealing with confidential information; 
you can feel assured that all information you disclose concerning yourself and your family 
will be kept in a confidential file which will be kept locked at all times.  This data will be 
stored for 10 years after collection. With your permission, data from this study may be used 
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in future related studies, which have been given ethical approval from a Health and Disability 
Ethics Committee. All information will be kept as group data.  Therefore, forms will be coded 
and names removed such that you cannot be identified. Confidentiality will be respected and 
no material which could personally identify you will be used in any reports on this study. 
However, in cases where we are concerned about your safety or the safety of others, we 
may decide to breach confidentiality.   
 
The results of the tests described above will be used for research purposes only in the 
context of this study.  We are happy to discuss any of the results found from the present 
study with you and discuss the questionnaires upon the completion of your participation. We 
would need your permission and signed consent to send these test scores to another 
professional involved in your care.  
 
What happens after the study? 
If you feel you have benefited at the end of the trial, and want to continue taking the 
supplement, it is commercially available. We can provide you with the contact information so 




If you have any queries or concerns regarding your rights as a participant in the study you 
can contact an independent health and disability advocate. This is a free service provided 
under the Health and Disability Commissioner Act. Telephone (NZ Wide) 0800 555 050, 
Free Fax (NZ wide): 0800 2787 7678 (0800 2 SUPPORT), Email (NZ wide) 
advocacy@hdc.org.nz. You can also contact Joanna Lothian, the principle investigator of 
this study at joanna.lothian@pg.canterbury.ac.nz or Dr. Julia Rucklidge, the supervisor of 
this research, on 364-2987 ext7959, should you have any questions or concerns about this 
research. The Human Ethics committee at the University of Canterbury has reviewed and 
approved this study. We have also consulted with The Maori Consultation Group at the 





     






Title of research project: Investigation into the effect of a micronutrient supplement on 
insomnia symptoms in adults; pilot study, multiple baseline design. 
 
Principal Investigator: Joanna Lothian,  
 
Other Investigators: Assoc Prof Julia Rucklidge, Assoc Prof Neville Blampied  
 
I have read and I understand the information sheet dated 31st October 2012 for volunteers 
taking part in the study designed to assess the impact of a micronutrient formula on 
symptoms of insomnia. I have had the opportunity to discuss this study. I am satisfied with 
the answers I have been given. I understand that taking part in this study is voluntary (my 
choice) and that I may withdraw from the study at any time and this will in no way affect my 
continuing health care. I also understand that I may withdraw any information already 
provided. 
 
I understand that my participation in this study is confidential and that no material which 
could identify me will be used in any reports on this study. I understand that the treatment, or 
investigation, will be stopped if it should appear harmful to me. I understand the 
compensation provisions for this study. I have had time to consider whether to take part. I 
know who to contact if I have any side effects to the study, or if anything occurs which I 
would consider a reason to withdraw from the study. I know who to contact if I have any 
questions about the study. 
 
 
I wish to receive a copy of the results                                                     YES/NO 
 
Participants should be advised that a significant delay may occur between data collection 
and publication of the results. 
 
I agree to my GP or other current provider being informed of my participation in this 
study/the results of my participation in this study.                                   YES/NO 
 
I consent to being contacted 3 months after completion of the study regardless of whether I 
chose to continue to take the micronutrients and at that point I can choose whether to 
complete questionnaires.                                                                               YES/NO 
 
I consent to my name being placed in a separate database so that I can be contacted in the 
future should there be other studies for me to participate in with the understanding that I can 
choose whether to participate in such studies or not. 
                      YES/NO 
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I consent to the use of my data for future related studies, which have been given ethical 






I hereby consent to participate. 
 
  







Printed name:  
  
Signature of person 
who gained consent: 
 
  













The person who may be contacted about the research is: 
 
Principle Investigator: Joanna Lothian, joanna.lothian@pg.canterbury.ac.nz 
 
Or: Assoc Prof Julia Rucklidge, Principal Investigator, 364-2987 ext 7959 
 
A signed copy of this consent form has been given to you to keep for your records and 
reference. Ingredients of Daily Self Defence attached. 
 
 









Ingredients of Daily Self Defense (W) (Revised formula of EMPowerplus) 







Vitamin A (as retinyl palmitate) 666.7 IU 2000.0 IU 4000.0 IU 
Vitamin C (as ascorbic acid) 50.0 mg 150.0 mg 300.0 mg 
Vitamin D (as cholecalciferol) 500.0 IU 1500.0 IU 3000.0 IU 
Vitamin E (as d-alpha tocopheryl 
succinate) 
43.7 IU 131.0 IU 261.9 IU 
Vitamin K1 (as phylloquinone) 15.0 mcg 45.0 mcg 90.0 mcg 
Vitamin K2 (as menaquinone-7) 5.0 mcg 15.0 mcg 30.0 mcg 
Thiamin (as thiamin mononitrate) 10.0 mg 30.0 mg 60.0 mg 
Riboflavin  2.7 mg 8.0 mg 16.0 mg 
Niacin (as niacinamide) 8.7 mg 26.0 mg 52.0 mg 
Vitamin B6 (as pyridoxine 
hydrochloride) 
10.0 mg 30.0 mg 60.0 mg 
Folate (as folic acid) 66.7 mcg 200.0 mcg 400.0 mcg 
Folate (as L-methylfolate calcium) 66.7 mcg 200.0 mcg 400.0 mcg 
Vitamin B12 (as methylcobalamin) 66.7 mcg 200.0 mcg 400.0 mcg 
Biotin  63.0 mcg 189.0 mcg 378.0 mcg 
Pantothenic acid (as d-calcium 
pantothenate) 
5.0 mg 15.0 mg 30.0 mg 
Calcium (as chelate) 81.0 mg 242.9 mg 485.8 mg 
Iron (as chelate) 3.0 mg 9.0 mg 18.0 mg 
Phosphorus (as chelate) 51.5 mg 154.6 mg 309.1 mg 
Iodine (as chelate) 40.0 mcg 120.0 mcg 240.0 mcg 
Magnesium (as chelate) 36.8 mg 110.4 mg 220.8 mg 
Zinc (as chelate) 2.9 mg 8.8 mg 17.7 mg 
Selenium (as chelate) 12.5 mcg 37.5 mcg 75.0 mcg 
Copper (as chelate) 0.4 mg 1.3 mg 2.6 mg 
Manganese (as chelate) 0.6 mg 1.8 mg 3.5 mg 
Chromium (as chelate) 38.3 mcg 114.9 mcg 229.8 mcg 
Molybdenum (as chelate) 8.8 mcg 26.4 mcg 52.8 mcg 
Potassium (as chelate) 14.7 mg 44.2 mg 88.3 mg 
Choline bitartrate  28.7 mg 86.1 mg 172.2 mg 
Shilajit  12.5 mg 37.5 mg 75.0 mg 
Spirulina  11.0 mg 33.0 mg 66.0 mg 
Larch arabinogalactan  11.0 mg 33.0 mg 66.0 mg 
Inositol  9.6 mg 28.7 mg 57.4 mg 
Rhodiola rosea root extract  6.7 mg 20.0 mg 40.0 mg 
Astragalus root extract  6.0 mg 18.0 mg 36.0 mg 
Royal jelly 3X  4.0 mg 12.0 mg 24.0 mg 
Grape seed extract  2.4 mg 7.2 mg 14.4 mg 
Ginkgo biloba leaf extract  1.9 mg 5.8 mg 11.5 mg 
Germanium sesquioxide (as chelate) 1.3 mg 3.8 mg 7.6 mg 
Boron (as chelate) 147.2 mcg 441.6 mcg 883.2 mcg 
Vanadium (as chelate) 73.2 mcg 219.7 mcg 439.4 mcg 
Lithium orotate (as chelate) 61.4 mcg 184.1 mcg 368.2 mcg 
Nickel (as chelate) 1.8 mcg 5.5 mcg 11.0 mcg 
Cellulose  55.2 mg 165.6 mg 331.2 mg 
Glycine  45.0 mg 135.0 mg 270.0 mg 
Citric acid  26.8 mg 80.4 mg 160.9 mg 
Magnesium stearate  24.0 mg 72.0 mg 144.0 mg 
Silicon dioxide  20.0 mg 60.0 mg 120.0 mg 








WEEKLY SLEEP DIARY                                            Name:      
Today’s Date Example 
4/5/11 
    
1. What time did you get into 
bed? 
10:15pm     
 2. What time did you try to go 
to sleep? 
11:30pm     
 3. How long did it take you to 
fall asleep? 
55 min     
4. How many times did you 




    
5. In total, how long did these 
awakenings last? 
2 hours,  
5 min 
    
6. What time was your final 
awakening? 
6:35am     
7. After your final awakening, 
how long did you spend in bed 
trying to sleep? 
 
45 min 
    
8. Did you wake up earlier 
than planned? 
Yes     
9. If yes, how much earlier? 1 hour     
10.  What time did you get out 
of bed for the day? 
7:20am     
11. In total, how long did you 
sleep? 
4 hours 10min     
12. How would you rate the 
quality of your sleep? 




o Very good 




o Very good 




o Very good 




o Very good 








Today’s Date Example: 4/5/11     
13. How rested or 
refreshed did you 
feel when you woke 
up for the day? 




o Well rested 
o Very well 
rested 




o Well rested 
o Very well 
rested 




o Well rested 
o Very well 
rested 




o Well rested 
o Very well 
rested 




o Well rested 
o Very well 
rested 
14. How many times 
did you nap or doze? 
2 times     
15. In total, how 
long did you nap or 
doze? 
1hour ,10min     
16. How many 
(standard) drinks 
containing alcohol 
did you have? 
2 drinks     
17. What time was 
your last drink? 
5:30pm     
18. How many 
caffeinated drinks 
(coffee, tea, soda, 
energy drinks) did 




1x espresso coffee 
1x instant coffee 
1x Green tea 
    
19. What time was 
your last caffeinated 
drink? 
3:30pm     





If so, list 
medication(s), dose, 










    
21. Did you take the 
full six capsules of 
Daily Self Defense? 
 








    
22. Any further 
comments or 
information you 
would like to add? 
 




General Instructions for completing your Sleep Diary 
What is a Sleep Diary? A sleep diary is designed to gather information about your daily 
sleep pattern. 
How often and when do I fill out the sleep diary? It is necessary for you to complete your 
sleep diary every day. If possible, the sleep diary should be completed within one hour of 
getting out of bed in the morning. 
What should I do if I miss a day? If you forget to fill in the diary or are unable to finish it, 
leave the diary blank for that day. 
What if something unusual affects my sleep or how I feel in the daytime? If your sleep 
or daytime functioning is affected by some unusual event (such as an illness, or an 
emergency) you may make brief notes on your diary. 
What do the words “bed” and “day” mean on the diary? This diary can be used for 
people who are awake or asleep at unusual times. In the sleep diary, the word “day” is the 
time when you choose or are required to be awake. The term “bed” means the place where 
you usually sleep. 
Will answering these questions about my sleep keep me awake? This is not usually a 
problem. You should not worry about giving exact times. And you should not watch the 
clock. Just give your best estimate. 
Sleep Diary Item Instructions 
Use the guide below to clarify what is being asked for each item of the Sleep Diary. 
Date: Write the date of the morning you are filling out the diary 
1. What time did you get into bed? Write the time that you got into bed. This may not be the 
time you began “trying” to fall asleep. 
2. What time did you try to go to sleep? Record the time that you began “trying” to fall 
asleep. 
3. How long did it take you to fall asleep? Beginning at the time you wrote in question 2, 
how long did it take you to fall asleep. 
4. How many times did you wake up, not counting your final awakening? How many times 
did you wake up between the time you first fell asleep and your final awakening? 
5. In total, how long did these awakenings last? What was the total time you were awake 
between the time you first fell asleep and your final awakening. For example, if you woke 
3 times for 20 minutes, 35 minutes, and 15 minutes, add them all up (20+35+15= 70 min 
or 1 hr and 10 min). 
6a. What time was your final awakening? Record the last time you woke up in the morning. 
6b. After your final awakening, how long did you spend in bed trying to sleep? After the last 
time you woke up (item 6a), how many minutes did you spend in bed trying to sleep? For 
example, if you woke up at 8am, but continued to try and sleep until 9am, record 1 hour. 
6c. Did you wake up earlier than you planned? If you woke up or were awakened earlier than 
you planned, check yes. If you woke up at your planned time, check no. 
6d. If yes, how much earlier? If you answered “yes” to question 6c, write the number of 
minutes you woke up earlier than you had planned on waking up. For example, if you woke 
up 15 minutes before the alarm went off, record 15 minutes here. 
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7. What time did you get out of bed for the day? What time did you get out of bed with no 
further attempt at sleeping? This may be different from your final awakening time (e.g. 
you may have woken at 6:35am but did not get out of bed to start your day until 7:20am) 
8. In total, how long did you sleep? This should just be your best estimate, based on when 
you went to bed and woke up, how long it took you to fall asleep, and how long you were 
awake in the night. You do not need to calculate this by adding and subtracting; just give 
your best estimate. 
9. How would you rate your quality of sleep? “Sleep Quality” is your sense of whether your 
sleep was good or poor. 
10. How restful or refreshed did you feel when you woke up for the day? This refers to how 
you felt after you were done sleeping for the night, during the first minutes that you were 
awake. 
11a. How many times did you nap or doze? A nap is a time you decided to sleep during the 
day, whether in bed or not in bed. “Dozing” is a time you may have nodded off for a few 
minutes, without meaning to, such as while watching TV. Count all the times you napped or 
dozed at any time form when you first got out of bed in the morning until you got into bed 
again at night. 
11b. In total, how long did you nap or doze for? Estimate the total amount of time you spent 
napping or dozing in hours and minutes. For instance if you napped twice, for 30 minutes 
and once for 60 minutes, and dozed for 10 minutes, you would answer “1 hour 40 minutes.” 
If you did not nap or doze, write N/A” (not applicable). 
12a. How many drinks containing alcohol did you have? Enter the number of alcoholic drinks 
you had the previous day, where 1 drink is defined as one 12 oz beer (can), one standard 
glass of wine, or one shot of liquor. 
12b. What time was your last drink? If you had an alcoholic drink yesterday, enter the time of 
day in hours and minutes of your last drink. If you did not have a drink write “N/A” (not 
applicable). 
13a. How many caffeinated drinks (coffee, tea, soda, energy drinks) did you have? Enter the 
number of caffeinated drinks you consumed yesterday. 
13b. What time was your last caffeinated drink? If you had a caffeinated drink, enter the time 
of day in hours and minutes of your last drink. If you did not have a caffeinated drink, write 
“N/A” (not applicable). 
14. Did you take any over-the-counter or prescription medication(s) to help you sleep? If so, 
list the medication(s), dose, and time taken: List the medication name, how much you took 
EACH different medication you took to help you sleep. Include medication available over the 
counter, prescription medications, and herbals. If every night is the same, write “same” after 


















Vitamin A  666.7 IU 2000.0 IU 4000.0 IU 
Vitamin C  50.0 mg 150.0 mg 300.0 mg 
Vitamin D  500.0 IU 1500.0 IU 3000.0 IU 
Vitamin E  43.7 IU 131.0 IU 261.9 IU 
Vitamin K1  15.0 mcg 45.0 mcg 90.0 mcg 
Vitamin K2  5.0 mcg 15.0 mcg 30.0 mcg 
Thiamin  10.0 mg 30.0 mg 60.0 mg 
Riboflavin  2.7 mg 8.0 mg 16.0 mg 
Niacin  8.7 mg 26.0 mg 52.0 mg 
Vitamin B6  10.0 mg 30.0 mg 60.0 mg 
Folate  66.7 mcg 200.0 mcg 400.0 mcg 
Vitamin B12  66.7 mcg 200.0 mcg 400.0 mcg 
Biotin  63.0 mcg 189.0 mcg 378.0 mcg 
Pantothenic acid  5.0 mg 15.0 mg 30.0 mg 
Calcium  81.0 mg 242.9 mg 485.8 mg 
Iron  3.0 mg 9.0 mg 18.0 mg 
Phosphorus  51.5 mg 154.6 mg 309.1 mg 
Iodine  40.0 mcg 120.0 mcg 240.0 mcg 
Magnesium  36.8 mg 110.4 mg 220.8 mg 
Zinc  2.9 mg 8.8 mg 17.7 mg 
Selenium  12.5 mcg 37.5 mcg 75.0 mcg 
Copper  0.4 mg 1.3 mg 2.6 mg 
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Manganese  0.6 mg 1.8 mg 3.5 mg 
Chromium  38.3 mcg 114.9 mcg 229.8 mcg 
Molybdenum  8.8 mcg 26.4 mcg 52.8 mcg 
Potassium  14.7 mg 44.2 mg 88.3 mg 
Choline bitartrate  28.7 mg 86.1 mg 172.2 mg 
Shilajit  12.5 mg 37.5 mg 75.0 mg 
Spirulina  11.0 mg 33.0 mg 66.0 mg 
Larch arabinogalactan  11.0 mg 33.0 mg 66.0 mg 
Inositol  9.6 mg 28.7 mg 57.4 mg 
Rhodiola rosea root 
extract  
6.7 mg 20.0 mg 40.0 mg 
Astragalus root extract  6.0 mg 18.0 mg 36.0 mg 
Royal jelly 3X  4.0 mg 12.0 mg 24.0 mg 
Grape seed extract  2.4 mg 7.2 mg 14.4 mg 
Ginkgo biloba leaf 
extract  
1.9 mg 5.8 mg 11.5 mg 
Germanium 
sesquioxide  
1.3 mg 3.8 mg 7.6 mg 
Boron  147.2 mcg 441.6 mcg 883.2 mcg 
Vanadium  73.2 mcg 219.7 mcg 439.4 mcg 
Lithium orotate  61.4 mcg 184.1 mcg 368.2 mcg 
Nickel  1.8 mcg 5.5 mcg 11.0 mcg 
Cellulose  55.2 mg 165.6 mg 331.2 mg 
Glycine  45.0 mg 135.0 mg 270.0 mg 
Citric acid  26.8 mg 80.4 mg 160.9 mg 
Magnesium stearate  24.0 mg 72.0 mg 144.0 mg 
Silicon dioxide  20.0 mg 60.0 mg 120.0 mg 
       
 
 
